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I. Abstract  1 
  2 
The  aim  of  this  study  was  to  investigate  the  influence  of  Angiotensin-I  3 
Converting Enzyme (ACE) genotype and the influence of circulating ACE activity  4 
on  the  extent  of  muscle  growth  and  strength  development  achieved  during  5 
strength training. It was hypothesized that ACE Deletion (D) allele carriers would  6 
have higher force output values before and after the 12 week strength training  7 
programme.  Forty  male  Caucasian  recreationally  active  volunteers  were  8 
genotyped  for  ACE  Insertion/Deletion  (I/D)  polymorphism,  but  only  eighteen  9 
subjects identified with the DD or the II genotype were qualified to participate.  10 
Eleven II and seven DD subjects underwent a 12 week strength training program  11 
for  the  quadriceps  muscle  group  of  the  trained  leg,  with  both  legs  assessed  12 
weekly by isokinetic dynamometry at joint angles of 30ﾰ, 60ﾰ and 90ﾰ(isometric  13 
knee extension) and 60ﾰ/sec and 180ﾰ/sec (isokinetic maximal torque). Biopsy  14 
samples were obtained from the vastus lateralis of the trained leg pre- and post- 15 
training,  and  they  were  analyzed  using  light  microscopy  and  computer-based  16 
planimetry to identify the cross-sectional area of each major fiber type as an  17 
index of hypertrophy. A number of histochemical staining methods (H&E, SDH,  18 
GPDH, IHC, mATPases) were used for delineation of the fiber types. Circulating  19 
ACE activity was determined in blood samples and DNA samples were extracted  20 
from saliva for genotyping. ACE genotype was not associated with circulating  21 
ACE activity, with DD individuals presenting similar plasma ACE activity levels  22 
with II individuals (39.7 ± 40 and 40.5 ± 3.30 respectively, P = 0.89 pre-training,  23 
41.9 ± 3.7 and 35.5 ± 4.30 respectively, P = 0.30 post-training). ACE activity did  24 
not  change  significantly  with  training  (40.2  ±  2.5  nmol  His-Leu/min/mL  pre- 25 
training, 38.1 ± 3 nmol His-Leu/min/mL post training, P = 0.41) and correlated  26 
significantly with baseline isometric force of the untrained leg at 5ﾰ (r = 0.46, P  27 
= 0.05) and isokinetic strength at 180ﾰ/sec (r = 0.52, P = 0.03). When strength  28 
was  presented  as  force  production  per  kilogram  of  body  mass,  the  above  29 
correlations  became  non-significant.  Isometric  force  at  60º  post-training  30 
revealed a significant effect of the genotype, in favour of the DD individuals, on  31 
the trained leg F (1, 64) = 4.242, P = 0.04, observed power = 0.53, partial eta  32 
squared = 0.062). The effect persisted after adjustment for weight, but when it  33 
was  adjusted  for  body  mass  index  and  physical  activity  (assessed  by  34 
questionnaires), the effect became non-significant (F (1, 63) = 3.13391, P = 0.08,  35   5 
partial eta squared = 0.047, observed power = 0.41); and F (1, 63) = 3.1628, P =  1 
0.08,  partial  eta  squared  =  0.048,  observed  power  =  0.42,  respectively).The  2 
average cross-sectional area (AVECSA) of Type IIA fibres for the DD individuals  3 
increased significantly post-training (4070 ± 506 μm² pre-training,  4674 ± 399  4 
μm² post-training, t (6) = -2.999, P = 0.02) and so did the AVECSA of the Type I  5 
fibers  of  II  individuals  (3345  ±  207  μm²  pre-training,  3988  ±  239  μm²  post- 6 
training, t (10) = -3.063, P = 0.01). The finding shows that the strength training  7 
programme applied resulted in muscle hypertrophy, but the changes in AVECSA  8 
were not genotype-related. In conclusion, our findings suggest a possible role for  9 
ACE gene polymorphism in the regulation of human skeletal muscle strength, but  10 
limited  statistical  power  and  confounding  factors  prevented  us  from  drawing  11 
clear conclusions.   12 
Key words: Angiotensin Converting Enzyme – skeletal muscle – training   13 
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1.Introduction  1 
  2 
1.1 Angiotensinogens and the Renin-Angiotensin System  3 
The  RAS  (Renin-Angiotensin  System)  is  a  peptidergic  system  with  endocrine  4 
characteristics that regulates blood pressure and fluid balance (see Fig.1.1). This  5 
system uses angiotensinogen as a substrate (an a-glycoprotein, released from the  6 
liver) (Menard et al., 1983; Deschepper, 1994; Hall, 2003), and it is cleaved in  7 
the circulation by the enzyme renin that is secreted from the juxtaglomerular  8 
apparatus of the kidney (Hackenthal et al., 1978; Sealey et al., 1977; Hall, 2003;  9 
Persson  et  al.,  2004)  to  form  the  decapeptide  angiotensin  I  (ANGI).  ANGI  is  10 
converted to Angiotensin II (ANGII) by the Angiotensin Converting Enzyme (ACE).  11 
ANGII is responsible for the constriction of blood vessels that lead to increased  12 
blood pressure and also stimulates the secretion of aldosterone from the adrenal  13 
cortex.  14 
  15 
  16 
Figure.1.1: The kinin– kallikrein, and renin–angiotensin systems, picture taken  17 
from  F.A.  Sayed-Tabatabaei,  B.A.  Oostra,  A.  Isaacs,  C.M.  van  Duijn,  J.C.M.  18 
Witteman, ACE polymorphisms, Circulation Research. 2006; 98:1123.  19 
   20 
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  1 
1.2 Angiotensin Converting Enzyme  2 
  3 
Angiotensin  converting  enzyme  (ACE),  key  component  of  the  RAS,  is  a  zinc  4 
metallopeptidase (kininase II, EC 3.4.15.1) which is predominantly expressed in  5 
high  concentrations  on  the  surface  of  endothelial  cells  in  the  pulmonary  6 
circulation (Ng et al., 1967; Wei et al., 1991; Corvol et al., 1995; Costerousse et  7 
al., 1998; Hall, 2003; Soubrier et al., 2003; Soubrier et al., 2003;). Its function is  8 
to convert angiotensin I (ANGI) (vasoinactive) into a biologically active hormone,  9 
angiotensin II (ANGII) (vasoconstrictor) (Bernstein et al., 1989). ACE is also an  10 
important regulator of the kinin-kallikrein system (see Fig.1.1).   11 
  12 
1.2.1 ANGII and AT1 / AT2 receptors  13 
  14 
ANGII, the main effector peptide of the RAS, is acting on specific receptors, for  15 
example,  to  induce  vasoconstriction  by  interacting  with  ANG  receptors  on  16 
vascular smooth muscle cells, or by stimulating the release of aldosterone from  17 
the  adrenal  cortex  (Hollenberg  et  al.,  1979;  Quinn  and  Williams,  1988;  Hall,  18 
2003).  In  humans,  ANGII  effects  are  mediated  predominantly  through  two  19 
specific  receptors,  namely  AT1  (ANGII  Type  I  receptor)  (vasoconstrictor  20 
responses) and AT2 (ANGII Type 2 receptor) (vasodilator responses), which are G- 21 
protein coupled receptors in plasma membrane (Crisan and Carr, 2000; Danser,  22 
2003). ACE also has the ability to hydrolyze numerous other peptide substrates  23 
(Hooper and Turner, 2003). There are two separate sources of ANGII; the first  24 
source  is  systemic  ANGII  from  the  RAS,  whereby  circulating  angiotensinogen  25 
produced by hepatocytes is converted to ANGI by renin released from the kidney  26 
and then to ANGII by ACE, which is bound to the capillary endothelium of various  27 
tissues (McBride, 2006). The second source of ANGII is a separate local RAS that  28 
has been identified in many tissues, which is stimulated by local signals such as  29 
cell stretch (Sadoshima et al. 1993), resulting in a local production and release  30 
of ANGII in an autocrine/paracrine manner (Sadoshima et al., 1993; Jones and   31 
Woods, 2003).   32 
  33 
34   13 
  1 
1.2.2 Local RAS in skeletal muscle  2 
  3 
Tissue RAS systems with all the necessary components for ANGII synthesis, have  4 
been  identified  in  a  number  of  peripheral  tissues  including  the  adipose,  the  5 
cardiac, and skeletal muscle tissue (Engeli et al., 1999;  Martin et al.,  2006),  6 
suggesting a paracrine action of the RAS (Lavoie and Sigmund, 2003). Local ACE  7 
expression may also modulate tissue growth processes as both ANGII and kinins  8 
appear to have growth regulatory effects. Geisterfer et al., (1988) in a study  9 
that was conducted on cultured aortic smooth muscle cells, found that ANGII is a  10 
potent  hypertrophic  agent  (Geisterfer  et  al.,  1988).  A  similar  research  was  11 
carried by Ishigai et al., (1997), demonstrating that kinins appear to play a role  12 
in  hypertrophy  of  cardiomyocytes  (Ishigai,  et  al.,  1997).  More  recently,  13 
immunohistochemistry  of  human  muscle  biopsies  has  localized  ACE  to  the  14 
endothelial  cells  of  capillaries  in  skeletal  muscle  (Schaufelberger,  Drexler,  15 
Schieffer, and Swedberg, 1998). Jones and Woods (2003) in an extensive review  16 
specified the relationship between exercise performance and a physiologically  17 
functional skeletal RAS (see table 1 for the skeletal muscle RAS constituents and  18 
Figure 1.2 for the effects of ANGII on muscle performance). They concluded that  19 
this local RAS system exists and it is capable of de novo ANGII production and  20 
interaction with the kallikrein-kinin system and therefore a significant potential  21 
for an influence on human performance arises (Jones and Woods, 2003).  22 
23   14 
  1 
  2 
  3 
Table 1: Summary of skeletal muscle RAS constituents. Source: Jones A., Woods  4 
D.R., Skeletal muscle RAS and exercise performance. Int J Biochem Cell Biol  5 
2003; 35(6):855-66.   6 
7 
RAS component   Presence     Location     Reference 
           
Angiotensinogen   Inferred  
 
Induction of local Ang I 
following renin infusion   Muller et al. (1997) 
ACE   Yes 
Local Ang I production in 
pigs  Danser et al. (1992) 
 
 
     
Endothelial cells of 
capillaries 
Schaufelberger et 
al. (1998) 
 
Skeletal muscle 
membrane  
Dragovic et al. 
(1996) 
Human muscle biopsies  
Reneland & Lithell 
(1994) 
 
 
     
ANGI–ANGII conversion   Yes 
Human skeletal muscle 
de novo synthesis   Danser et al. (1992) 
 
Peripheral muscle 
vascular bed 
 Saris et al. (2000); 
van Dijk et al. (2000) 
Skeletal muscle 
membrane   Ward et al. (1995) 
   
 
 
     
AT1 receptor   Yes  
Rat skeletal muscle fibre 
and microvessels  
Linderman & 
Greene (2001) 
AT2 receptor  
 
Human skeletal muscle  
Malendowicz et al. 
(2000) 
 
 
     
Yes  
Rat skeletal muscle fibre 
and microvessels  
Linderman & 
Greene (2001)   15 
  1 
  2 
  3 
Figure 1.2: Effects of ANGII on muscle performance. Source: Jones A., Woods  4 
D.R., Skeletal muscle RAS and exercise performance. Int J Biochem Cell Biol  5 
2003; 35(6):855-66.   6 
  7 
Taking  into  account  the  above  (see  Figure  1.2),  RAS  does  influence  smooth  8 
muscle  and cardiac muscle  growth,  and might thus be  expected to influence  9 
skeletal muscle growth. So on that basis, research shows that ANGII is necessary  10 
for mediating load-induced skeletal muscle growth. ACE gene expression also is  11 
variable and, quantified by the number of ACE-mRNA transcripts, is related to  12 
muscle  fibre  area  with  an  inverse  relationship  to  capillary  density  13 
(Schaufelberger et al. 1998)  14 
  15 
  16 
  17 
  18 
  19 
  20 
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  1 
1.2.3. The ACE I/D polymorphism  2 
  3 
During the last few decades more and more scientists are focusing their research  4 
on  genetics.  Since  the  launching  of  the  Human  Genome  Project,  many  5 
interesting  discoveries  have  been  made  especially  in  the  fields  of  clinical  6 
science, where genes responsible for certain diseases have been identified. The  7 
genome  of  a  single  person  may  be  a  predisposing  factor  to  some  certain  8 
pathological situations, and may have an impact on the response to treatment.  9 
Genetic  data  is  available  for  some  phenotypes  having  to  do  with  physical  10 
performance;  these  include  cardio  respiratory  endurance,  elite  endurance  11 
athlete status, muscle strength, other muscle performance traits, and exercise  12 
intolerance  of  variable  degrees  (Bray  et  al.,  2008).  Many  researchers  have  13 
identified  ACE  as  a  candidate  gene  affecting  an  individual‘s  endurance  or  14 
strength capacity (Gaygay et al., 1998; Folland et al., 2000; Jones et al., 2002;  15 
Williams  et  al.,  2005),  with  Hugh  Montgomery  being  the  first  one  to  do  so  16 
(Montgomery et al., 1997). The ACE gene is highly polymorphic, with over 100  17 
polymorphisms  listed  in  SNPs  database  (http://www.ncbi.nlm.nih.gov- 18 
/sites/entrez,ID=1636). A polymorphism of the ACE gene that is associated with  19 
a change in ACE activity has been identified, with the absence (deletion allele,  20 
D) rather than the presence (insertion allele, I) of a 287 base-pair fragment in  21 
intron 16 of the ACE gene (see Fig. 1). Each human has 2 alleles, therefore three  22 
genotypes  exist:  II,  ID  and  DD,  the  distributions  of  which  within  a  Caucasian  23 
population are roughly 25, 50 and 25%, respectively.   24 
25   17 
  1 
  2 
  3 
Figure 1.3: Intron 16 of the human ACE gene where the 287 base pair fragment  4 
responsible for the I/D polymorphism is located. Figure adapted from Prof. Hugh  5 
Montgomery, UCL.  6 
  7 
1.2.4. Effects on plasma circulating ACE activity  8 
This  polymorphism  accounts  for  almost  half  of  the  variance  in  plasma  ACE  9 
activity as well, with homozygotes for the D allele  showing higher plasma ACE  10 
levels,  than  individuals  with  the  ID  (intermediate  ACE  levels)  and  individuals  11 
with the II (lower ACE levels) genotypes (Rigat et al., 1990)(see figure below).  12 
Danser et.al (1995) associated the DD genotype with higher cardiac ACE activity,  13 
which  may  result  in  increased  cardiac  ANGII  levels,  which  makes  this  a  14 
mechanism  underlying  the  reported  association  between
  the  ACE  deletion  15 
polymorphism and the increased risk for several cardiovascular
 disorders, such as  16 
myocardial  infarction,
 cardiomyopathy, left  ventricular  hypertrophy,  and  17 
coronary
 artery diseases (Danser et al., 1995).  18 
  19   18 
  1 
Figure 1.4: (Original figure from Rigat et al., 1990): Serum immunoreactive ACE  2 
concentrations  (μg/liter)  for  individual  with  the  II,  ID,  and  DD  genotypes,  3 
respectively, shown in left, middle, and right panels. Solid vertical bars indicate  4 
mean concentration and standard deviation for each group.  5 
  6 
 The concentration of circulating ACE activity is associated with ACE genotype  7 
(Rigat et al., 1990, see also Fig 1.2). Each peptide/ protein has a free amino  8 
group and a free carboxyl group. The residue bearing the free amino group is  9 
termed the amino terminal or N-terminal residue, whereas the residue bearing  10 
the free carboxyl group is termed the carboxyl terminal or C-terminal residue.  11 
Almeida (Almeida et al., 2010) found that the total plasma ACE activity of both  12 
domains  (N-  and  C-  terminus)  in  II  individuals  was  significantly  lower  in  13 
comparison to ID and DD, so the I/D ACE polymorphism affects differently both  14 
ACE domains.   15 
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  1 
1.3 Skeletal muscle fiber types   2 
  3 
Muscle fibres are formed by a fusion of a number of myoblasts into a single  4 
multinucleated cell. Based on their specific myosin heavy chain content (MHC),  5 
those fibres are classified in three major categories: (1) Type I (slow-oxidative  6 
fibres),  (2)  Type  IIA  (fast-oxidative  fibres),  and  (3)  Type  IIB  (fast-glycolytic  7 
fibres). Skeletal muscle fibres differ in contractile and metabolic characteristics,  8 
differences shown in Table 1.  9 
  10 
Table 2: Characteristics of the three major fiber types.  11 
  12 
Source: Vincent, B., 2009.Role of the Alpha-Actinin-3 R577X polymorphism in  13 
metabolic  and  contractile  properties  of  skeletal  muscle.  PhD,  Katholieke  14 
Universiteit  Leuven,  Group  Biomedical  Sciences  (Type  IIB  fibres  are  often  15 
referred in the literature as IIx).   16 
  17 
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As we can see from above, muscular efficiency (in terms of force production per  2 
unit ) is related to the type of muscle fiber, and more specific, Type I fibres are  3 
more efficient then Type II fibres when a contraction is performed isometrically  4 
or in a low velocity according to Coyle and his colleagues (1992). Given that the  5 
plasticity of the skeletal muscle fibres is extended (changes in muscle fibre size  6 
and transition between Type IIA and Type IIB), it is expected that changes will  7 
occur with specific training.   8 
  9 
1.4 ACE and adaptation to training  10 
1.4.1 Skeletal muscle growth  11 
The importance of ACE in the regulation of skeletal muscle growth was proved  12 
when  Gordon  et  al.,  (2001)  used  an  experimental  model  of  compensatory  13 
hypertrophy in Sprague-Dawley rats, by inducing optimal overload on a muscle.  14 
Oral ACE inhibitors were administered and prevented hypertrophy, while local  15 
ANGII perfusion of muscle rescued this. Oral sartans, which are a class of drugs  16 
which  inhibit  the  AT1  receptor,  also  inhibited  hypertrophy,  and  couldn‘t  be  17 
rescued with ANGII perfusion (Gordon et.al, 2001). McBride et al., (2006) found  18 
that  blocking  ANGII`s  AT1  receptor  attenuated  eccentric  training–induced  19 
hypertrophy and strength gains in Sprague–Dawley rats (McBride et al., 2006), a  20 
fact  that  provided  additional  evidence  for  the  role  of  the  renin–angiotensin  21 
system (RAS) in overload-induced muscle hypertrophy. Despite of all the above,  22 
the  mechanisms  by  which  ANGII  mediates  skeletal  muscle  hypertrophy  under  23 
conditions  of  overload  are  still  unknown.  However,  no  similar  study  has  yet  24 
directly evaluated the role of ACE in the regulation of skeletal muscle growth in  25 
humans.  26 
  27 
  28 
  29 
  30 
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1.4.2 Strength development  2 
  3 
Based on the previous studies that associated the D allele with the growth of  4 
vascular smooth muscle at the site of coronary angioplasty and human cardiac  5 
hypertrophy  in  response  to  exercise  (Ohishi  et  al.,1993;  Montgomery  et  al.,  6 
1997), and since Reneland and Lithell (1994) developed a technique that proved  7 
that  there  is  considerable  ACE  activity  in  skeletal  muscle,  Folland  (2000)  8 
investigated  the  influence  of  the  ACE  deletion  allele  on  the  response  of  the  9 
human quadriceps muscle group to specific strength training programmes in non- 10 
pathological population (Folland et al.,2000). Hence, this study used genotype as  11 
an  indirect  marker  of  ACE  activity,  and  compared  the  responses  to  strength  12 
training (Folland, et al., 2000). This study reported greater maximum voluntary  13 
contraction  (MVC)  and  similar  one-repetition  maximum  (1RM)  (Folland  et  al.,  14 
2000)  gains  after  resistance  training  among  subjects  with  the  ACE  D  allele  15 
compared with those with the ACE II genotype individuals with at least one D  16 
allele (Folland, et al., 2000).  17 
  18 
This finding is consistent with the key role of ACE in the regulation of skeletal  19 
muscle hypertrophy in rats (Gordon et al., 2001), but comes in contrast with the  20 
study of Montgomery (Montgomery et.al, 1999) where the I and not the D allele  21 
was associated with a greater relative whole-body anabolic response to training  22 
(Montgomery  et.al,  1999).Thus,  those  studies  are  not  comparable  since  23 
Montgomery et.al, (1999) used basic army training, at which physical activity is  24 
not specific, but rather wide and varied. Thomis et al., (1998) failed to support  25 
the relationship between the D allele and muscle strength adaptation to strength  26 
training. More specifically, Thomis et al., (1998) reported borderline significance  27 
for greater concentric flexion torque gains for ACE I allele carriers but found no  28 
associations  among  the  ACE  ID  genotype  and  the  muscle  size  response  to  29 
resistance training of the elbow flexors (Thomis et al., 1998). Pescatello et al.,  30 
(2006) on the other hand,  examined the influence of the ACE ID genotype on the  31 
muscle strength and size adaptations to a standardized 12-wk unilateral, upper- 32 
arm  resistance  training  intervention  in  a  large  sample  of  apparently  healthy  33 
young  adults  (Pescatello  et  al.,  2006).  It  was  hypothesized  that  the  muscle  34 
strength and size gains from resistance training would be greater among ACE DD  35   22 
homozygotes compared to carriers of the ACE I allele. In fact, training the non- 1 
dominant arm showed slight increases in strength, which were greater for the I  2 
allele, but D-allele dependent increases in strength of the dominant (untrained)  3 
arm (Pescatello et al., 2006).   4 
  5 
Charbonneau  et  al.  (2008)  on  the  contrary,  examined  this  association  in  the  6 
weight-bearing lower limbs, hypothesizing that the D allele would be associated  7 
with higher values for muscle phenotypes before strength training, and greater  8 
increases in muscle phenotypes in response to strength training (Charbonneau et  9 
al.,2008). Two hundred forty three inactive healthy volunteers (86 men and 139  10 
women), of mean age 62 years old, were studied before and after 10 weeks of  11 
unilateral knee extensor (Charbonneau et al., 2008). In this study, ACE genotype  12 
was  associated  with  baseline  differences  in  muscle  volume  but  it  was  not  13 
associated  with  the  muscle  hypertrophic  response  to  strength  training  14 
(Charbonneau et al., 2008). There is also a handful of other studies that have  15 
found no association between ACE and performance (Karjalainen et al., 1999;  16 
Taylor et al., 1999; Rankinen et al., 2000; Sonna et al., 2001; Zhao et al., 2003;  17 
Thomis et al., 2004; Scott et al., 2005).The reason for this noted inconsistency  18 
in the existing literature may be a result of limitations occurring in association  19 
studies. As Jones and his colleagues (2002) noted, even if an association is found  20 
between the ACE I/D polymorphism and human performance, there are many  21 
possible explanations for the relationship. Some possible scenarios may be the  22 
polymorphism  itself,  the  locus  within  which  the  polymorphism  is  located,  or  23 
another  locus  that  is  in  linkage  disequilibrium  with  the  polymorphism  to  be  24 
responsible for the association (Jones et al., 2002). Additionally, an association  25 
does not mean that this is the only cause. For example, an association between  26 
a gene and a certain physical characteristic does not mean that the gene caused  27 
or created the physical trait. Furthermore, population association studies have a  28 
tendency to present other difficulties. For example, variation within the control  29 
group  can  be  a  confounding  factor,  especially  when  the  frequency  of  the  30 
polymorphism  varies  among  control  populations  (Jones  et  al.,  2002).  Further  31 
research  is  required  in  humans  to  correlate  ACE  activity  directly  with  the  32 
training  response  (rather  than  using  the  genetic  marker  alone),  and  also  to  33 
measure skeletal muscle growth directly (rather than measuring muscle strength  34 
alone).   35   23 
  1 
1.5 Hypotheses  2 
  3 
  4 
Bearing in mind these findings, we posed the following hypotheses:  5 
1.  Baseline strength will be higher in homozygotes for the D allele compared  6 
to homozygotes for the I allele.  7 
  8 
2.  Type II fibres of homozygotes for the D allele will show more hypertrophy  9 
than  I  homozygotes  for  the  I  allele  in  response  to  a  strength  training  10 
programme.  11 
  12 
3.  There  will  be  a  difference  in  strength  development  between  the  13 
homozygotes for the I allele and homozygotes for the D allele in response  14 
to a strength training programme. Based on a biological rationale and the  15 
existing literature, homozygosity for the D allele will be favoured.  16 
  17 
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2. Methods and materials  2 
  3 
The study had appropriate ethics committee approval (Faculty of Biomedical and  4 
Life Sciences Ethics Committee). Written informed consent was obtained from  5 
all participants. The study was conducted with both assessors and subjects blind  6 
to the subjects‘ ACE genotype and activity.  7 
  8 
2.1 Subjects  9 
  10 
Subject eligibility was based on ACE genotype. In the initial phase of the study,  11 
40  male  Caucasian  recreationally  active  volunteers  were  recruited  from  the  12 
student and staff populations of The University of Glasgow, but only 18 subjects  13 
were  eligible  to  participate  as  they  fulfilled  the  genotype  criterion  (only  14 
subjects carrying the DD and II genotype were qualified to participate). Physical  15 
activity  levels  for  each  subject  were  recorded  via  questionnaires,  with  all  16 
participants not having taken part in any structured strength-training programme  17 
of the quadriceps muscle group during the 6 months preceding the initiation of  18 
the study. The activity stated was walking, cycling and recreational rugby and  19 
football. Exclusion criteria were medical problems (such as knee pathology or  20 
other  orthopaedic  conditions)  that  would  confound  their  participation  in  the  21 
study, or the use of any medication, including nutritional supplements, anabolic  22 
compounds  or  ACE  inhibitors/angiotensin  receptor  blockers.  Eligibility  was  23 
further  assessed  by  interview  and  further  by  completion  of  a  medical  and  a  24 
physical  activity  questionnaire.  Subjects  were  required  to  read  and  sign  the  25 
enclosed information sheet.  26 
Power analysis was conducted using the software package, G*Power 3.1.2 (Faul  27 
and Erdfelder, 1992-2009). We aimed to have at least 80 % power to detect a  28 
significant two-tailed correlation of magnitude r = 0.40 on the basis of an alpha  29 
of 0.05, which would require 46 subjects for both baseline and training analyses  30 
according  to  the  a-priori  analysis.  For  the  two-way  ANOVA  for  repeated  31   25 
measures,  sample  size  estimates  were  calculated  a  priori  on  the  basis  of  an  1 
alpha of  0.05  to  detect  a  medium  effect  size  of    0.25  (according to Cohen's  2 
effect size conventions between the two groups) with a desired power of 80 %,  3 
which would require a total sample size of 44 subjects. Post-hoc power analysis  4 
was performed in order to compute the power achieved given our sample size,  5 
(total sample N=18, sample size group 1 = 11, sample size group 2 = 7) to detect  6 
a significant difference between the two genotype groups (α= 0.05, effect size d  7 
= 0.5, two-tails) and, unfortunately, our study was considered underpowered (p  8 
=  0.16).  We  were  underpowered  for  genotype-specific  comparisons,  so  those  9 
analyses should be considered exploratory.  10 
2.2 ACE genotyping  11 
  12 
All volunteers underwent DNA sampling prior to the start of testing in order to  13 
distinguish those subjects with the preferred genotypes II and DD.  Heterozygous  14 
subjects with the ID genotype were excluded from this experiment as they are  15 
associated with both high and low levels of ACE activity (Cox et al., 2002).  The  16 
homozygous genotypes would present a noticeable variation in ACE production,  17 
and in turn discernable differences in muscle hypertrophy.  18 
DNA was collected from cells taken using a buccal swab from each volunteer.  19 
The  buccal  swabs  were  stored  in  1-mL  cell  lysis  solution  until  extraction.The  20 
genomic  DNA  was  extracted  from  the  cells  using  the  standard  Machery-Nagel  21 
‗NucleoSpin‘  protocol  for  human  tissue  (Machery-Nagel  07/03/Rev  02).  ACE  22 
genotype was determined using a polymerase chain reaction (PCR) (O‘Dell et al.,  23 
1995, Tsai et al., 2002).  This particular PCR method involved the use of a three- 24 
primer system; a forward primer which recognised the deletion (D) sequence, a  25 
forward  primer  which  recognised  the  insertion  (I)  sequence  and  a  common  26 
reverse  primer.  The  forward  deletion  primer  was  (5‘- 27 
CTCTAGACCTGCTGCCTATTACAGTC-3‘),  the  forward  insertion  primer  was  (5‘- 28 
CGGGATGGTCTCGATCTC-3‘)  and  the  common  reverse  primer  was  (5‘- 29 
CCCTCCCATGCCCATAAC-3‘).    The  PCR  protocol  for  the  I/D  polymorphism  30 
consisted  of  35  cycles  of  45  seconds  of  denaturation  at  94,  45  seconds  of  31 
annealing at 56.5, and 45 seconds of extension at 72. Cycling was preceded by  32 
7 minutes of denaturation at 94 and followed by 10 minutes of extension at 72.  33 
PCR products were resolved on a 2 % Agarose gel and visualised by ethidium- 34   26 
bromide staining by two independent staff blind to all subject data.  If present in  1 
the template DNA, the D allele yielded a product of 197 bp and the I allele a  2 
product  of  252  bp.  The  D  allele  in  heterozygous  samples  is  preferentially  3 
amplified; therefore each sample that was found to have the DD genotype was  4 
subject  to  a  second,  independent  PCR  amplification  with  a  primer  pair  that  5 
recognises an insertion-specific sequence to avoid mistyping the DD genotype. On  6 
completion of DNA genotyping, subjects with the appropriate genotype (II or DD)  7 
were notified of their qualification and invited to take part in the remainder of  8 
the experiment.  9 
  10 
2.3 Determination of plasma ACE activity (circulating)  11 
Before and after the 12 week intervention period, a resting blood sample (20- 12 
mL)  was obtained from a superficial forearm vein for analysis of plasma ACE  13 
activity.  Plasma  was  separated  immediately  from  10  mL  of  whole  blood  by  14 
centrifugation at 1500 g for 10 minutes and stored at -80 C until analysis. The  15 
remaining  10  mL  were  stored  for performing  the  ACE  genotyping,  but it  was  16 
finally decided to perform the above using saliva samples, so it was discarded.  17 
ACE  activity  was  assayed  using  a  spectrophotometric  technique  (Sigma  18 
Diagnostics,  Poole,  UK)  based on  the  method developed  by  Holmquist  et al.,  19 
(1979). The analysis was performed at the Institute of Pharmacology, University  20 
Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany, from Professor Peter  21 
Gohlke. The investigators remained blind to the subject's genotype.   22 
  23 
  24 
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 2.4 Muscle fibre analysis  2 
  3 
2.4.1 Obtaining the biopsies  4 
At least 7 days prior to initial strength testing and no later than 7 days post- 5 
intervention testing, skeletal muscle samples were taken from each subject. The  6 
biopsies were obtained by Dr. Kingsmore (FRCS (Gen), FRCS (Ed), MD, MB ChB, B  7 
Med Biol). The skeletal muscle sample was obtained from the vastus lateralis of  8 
the subjects‘ trained leg by the Bergström needle biopsy technique (Bergström,  9 
1975) as previously approved by the FBLS committee. Vastus lateralis, a portion  10 
of  the  quadriceps  femoris  muscle  group,  has  been  the  muscle  of  choice  for  11 
biopsies  due  to  several  advantages,  such  as  mixed  fiber  type  composition,  12 
trainability, and accessibility. Hence, a large set of data concerning this muscle  13 
exists in the literature, potentially facilitating comparisons among studies (Saltin  14 
and Gollnick, 1983).  15 
  16 
  17 
Figure 2.1: Muscle biopsy performed by the Bergströom needle biopsy technique.  18 
  19 
  20 
  21 
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2.4.2. Processing of the biopsies  2 
  3 
Muscle biopsy is an invasive procedure widely used to assess a number of  4 
structural and functional characteristics of  muscle tissue including fibre  5 
type  and  size,  enzymatic  capacity,  mitochondrial  concentrations,  6 
metabolic responses and contractile proteins. The skeletal muscle samples  7 
were  immediately  mounted  in  an  embedding  medium  (Optimal  Cutting  8 
Temperature Compound, OCT) and frozen in isopentane cooled with liquid  9 
nitrogen as described previously (Shono et al., 1999, Shono et al., 2001,  10 
Zhang et al., 2003). Serial 10µM cross-sections were cut using a Cryostat  11 
(Cryostat Jung Frigocut 2800E, Leica) at -20ﾰC. Samples were stained for  12 
five  different  staining  methods:  Haematoxylin  and  Eosin  (H&E),  SDH  13 
(Succinate Dehydrogenase), a-GPD (Glycerol-3-phosphate dehydrogenase),  14 
mATPase, (myosin ATPases) and IHC (immunohistochemistry). In order to  15 
identify  the  muscle  fibres  based  on  their  properties  (contractile,  16 
oxidative, etc), a comparison between identical fields while performing  17 
the  light  confocal  microscopy  analysis  was  essential  [Zeiss  (Axiophot,  18 
AxiocamMR3, Axioskop 2), microscope with film and digital capture].  19 
  20 
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Figure2.2: Comparison of frozen sections stained for myofibrillar ATPase at (A)  2 
pH 4.3 (B) pH 4.6, and (C) pH 9.4, and  by (D) immunohistochemistry for slow  3 
(dark grey) and pink (fast) myosin [Type I fibres are dark grey whereas type IIA  4 
and IIB fibres are distinguishable as pale greyish pink and pink, respectively. (E)  5 
SDH. [Original magnification, x100.]  6 
  7 
2.4.3. Staining with succinate dehydrogenase: Identifying oxidative potential  8 
  9 
The histochemical assay for SDH is used to distinguish between oxidative and less  10 
oxidative fibres. The activity of SDH was determined in 10-μm thick sections cut  11 
on a cryostat (Cryostat Jung Frigocut 2800E, Leica). The protocol used was the  12 
one previously described by Martin et al., (1988), with a slight alteration on the  13 
proportion analogous to the quantity of the tissue to be analysed. The solutions  14 
used were 100 mM of phosphate buffer containing the following solutions: A) 0.2  15 
M  NaH2PO4  H2O  (monosodium  phosphate  monohydrate)  [27.6  g/L]  B)  0.2  M  16 
Na2HPO4  2H2O  (Disodium  Phosphate  Dihydrate)  [35.6  g/L].  For  the  pH  7.4  17 
solution, 9.5 mL of A was mixed with 40.5 mL of B along with 50 mL of distilled  18 
water. For the pH 7.6 solution, 6.5 mL of A was mixed with 45.5 mL of B and 50  19 
mL of distilled water. The second solution used was 1 mM of sodium azide, which  20   32 
consisted of 0.065 g of sodium azide, 100 mL of distilled water, and then we  1 
dissolved the above solution to 100 mL. The third solution was 1 mM phenazine  2 
methosulphate (PMS) which was made of 0.03 g of PMS dissolved in 100 mL of  3 
distilled  water.  As  those  solutions  were  photosensitive,  they  were  prepared  4 
quickly  and  stored  in  the  dark.  The  incubation  medium  for  succinate  5 
dehydrogenase was 80 mL of phosphate buffer, pH 7.6 [100 mM], 1 mM sodium  6 
azide [1 mL, 10 μM], 0.12 g nitro blue tetrazolium [1.5 mM], and 0.19 g of EDTA  7 
[5 mM], 1.3 g of dissodium succinate [48 mM]. A further adjustment to pH 7.6  8 
may  have  been  necessary.  After  this  step,  2  mL  of  1  mM  PMS  [20  μM]  were  9 
dissolved to 100 mL of phosphate buffer [pH 7.6]. Sections were then incubated  10 
at 37 ﾰC in the dark for 15-60 minutes, depending on the staining intensity of the  11 
fibres. Mounting and dehydration followed as it is discussed at the IHC protocol.  12 
2.4.4 Glycerol-3-phosphate dehydrogenase (GPDH): Identifying    13 
glycolytic potential  14 
  15 
The  αGPD enzyme is used to distinguish among fibres based on their relative  16 
glycolytic potential. The GPDH activity was determined on 10 μM thick sections  17 
in a medium containing 100 mM  phosphate buffer (pH=7.4), 1.5 mM nitro blue  18 
tetrazolium, 9.3 mM Glycerophosphate, 20 μM PMS. The sections were incubated  19 
at  37  ﾰC,  in  the  dark,  for  15-60  minutes  (or  until  at  least  some  fibres  were  20 
strongly blue in colour). After that, the sections were dehydrated and mounted  21 
as described before (IHC Protocol).  22 
  23 
2.4.5 mATPases  24 
  25 
The standard ATPase method (Round et al., 1980) was used at pH values of 9.4,  26 
4.6, and 4.3 on the frozen tissue samples, together with a negative control. For  27 
each  case,  two  10μm  serial  sections  were  used,  so  that a  total  of  eight  was  28 
required. The ATPase preparations were done as part of the usual routine series  29 
of muscle stains (haematoxylin and eosin). The reagents used were as follows:  30   33 
Glycine buffer (7.5 g glycine and 5.8 g sodium chloride made up to 1 L with  1 
distilled water), buffered CaCl2 (Calcium chloride) (500 mL glycine buffer and  2 
100 mL 1 M calcium chloride and approximately 350 mL 0.1 M NaOH adjusted to  3 
pH 9.5 with 1 M NaOH.), acetate buffer pH 4.3 (36.8 mL 0.2 M acetic acid and  4 
3.2  mL  0.2  M  sodium  acetate  made  up  to  100  mL  with  distilled  water),  ATP  5 
[(disodium salt, Sigma Chemicals Ltd): for the working solution 5 mg is dissolved  6 
in a few drops of distilled water] dithiothreitol (DTT):[1 mM (renewed monthly)],  7 
cobalt chloride (2% solution), ammonium sulphide (1 % solution made up freshly  8 
from  a  concentrated  stock  solution  just  before  use),  calcium  chloride  (1  %  9 
solution), reaction mixture(1 drop of DTT (1 mM) and the ATP working solution  10 
added to 10 mL buffered CaCI2). The routine ATPase method (pH 9.4) was carried  11 
out as follows: Cryostat sections were cut at 10 μΜ and mounted on cover slips.  12 
Then, the sections were incubated in reaction mixture in a Colombia jar for 30  13 
min at 37 ﾰC and washed well in 1 % CaCl2 for 3 x 2 min periods. After that, they  14 
were placed in 2 % CoCl2 (Cobalt Chloride) solution for 2 x I min periods and then  15 
washed very thoroughly in at least 4 changes of distilled water. The sections  16 
were then placed in 1 % ammonium sulphide solution for 30 s (this step was  17 
carried out in a fume cupboard). After the color was developed, the sections  18 
were washed well with distilled water and mounted in tissue mount. The reverse  19 
ATPase method was carried out as follows: The sections were pre-incubated in  20 
pH 4.3 or 4.6 acetate buffer at 37 ﾰC for 10 min, washed quickly in dilute (1:4  21 
v/v) buffered CaCl2 and processed as for the routine ATPase reaction, but with  22 
the buffered CaCl2 diluted 1:4 with distilled water before the addition of the ATP  23 
and DTT. The ATP and calcium ions in the reaction mixture are in large excess  24 
which ensures maximum rates of ATP splitting and complete precipitation of the  25 
phosphate  formed.  The  ionic  strength  of  the  pH  9.4  incubating  solution  26 
maximizes  the  differentiation  of  the  two  fiber  types.  In  the  reverse  ATPase  27 
reaction, the activity of the type I fibres is preserved by diluting the buffered  28 
calcium before the addition of the ATP.  29 
  30 
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2.4.6. Immunohistochemistry  2 
  3 
Two 10 μm sections from each case were placed on one slide. The protocol used  4 
was almost identical to the one used before by Behan et al., (2002). The control  5 
consisted  of  one  section  of  each  18  subjects,  blocked  in  the  first  antibody.  6 
Commercial antibodies to fast and slow isoforms of myosin were used, each with  7 
a different visualization system, so that specific identification of each fiber type  8 
on the same section was feasible. After fixation in acetone for 10 minutes, the  9 
slides were placed in peroxide, washed with PBS (Phosphate Buffer Saline), and  10 
blocking serum was applied for 1 h. The antibody to slow myosin was applied,  11 
followed by a peroxidase biotinylated rabbit antimouse antibody; the result was  12 
visualized  as  black  type  I  fibres  using  the  commercial  Vector  SG  Peroxidase  13 
Substrate kit (Vector Laboratories, Peterborough, UK). The alkaline phosphatase  14 
conjugated antibody to fast myosin was then applied; red type II fibres were  15 
visualized using the commercial Vector Red substrate kit. The full details of the  16 
simple  standard  protocol,  used  widely  in  routine  pathology  laboratories  and  17 
which was slightly modified, are as follows.  18 
Sections were incubated with 20 % normal goat serum (NGS) in Tris buffered  19 
saline pH 7.6 (TBS) for 1 h, after which the excess serum was drained off and the  20 
sections  incubated  in  monoclonal  antibody  to  slow  myosin  (Sigma-  Aldrich,  21 
Poole, Dorset, UK) diluted 1/1000 in Blocking Serum (BS) for 1 h, followed by  22 
three washes in PBS. The sections were then incubated in peroxidase conjugated  23 
rabbit antimouse antibody (Dako Ltd, Ely, and Cambridgeshire, UK), diluted 1/50  24 
in BS, for 60 min, and then washed three times in PBS. Vector SG peroxidase  25 
substrate  solution  (Vector  Laboratories)  was  then  applied,  controlling  the  26 
reaction by microscopic examination over 5 to 15 min (Behan et al., 2002). The  27 
sections were washed 3 times in distilled water (DW), incubated in BS for 1 h.  28 
Excess  serum  was  drained  off  before  incubation  in  alkaline  phosphatase  29 
conjugated monoclonal antibody to fast myosin (Sigma- Aldrich), diluted 1/50 in  30 
BS, and the sections were incubated overnight in the refrigerator (4 ﾰC). After  31 
washing  3  times  in  PBS,  the  sections  were  incubated  in  Vector  red  alkaline  32 
phosphatase substrate solution (Vector Laboratories) for 10–20 min, controlling  33 
the  reaction  by  microscopic  examination.  The  final  wash  was  in  running  tap  34   35 
water, after which the sections were dehydrated through graded alcohols (70 %,  1 
90  %, 100 % times two, Tissue Clear times two) cleared in xylene, and mounted  2 
in synthetic medium ( Tissue Mount). The antibodies used were: (1) for type I  3 
fibres, monoclonal antimyosin (skeletal, slow; clone NOQ7.5.4D; Sigma-Aldrich).  4 
(2) For type II fibres, monoclonal antimyosin (skeletal, fast; alkaline phosphatase  5 
conjugate; clone MY-32; Sigma-Aldrich). On completion, type I fibres were black  6 
whereas  the  type  2  fibres  were  pink.  Type  IIA  and  IIB  subtypes  could  be  7 
distinguished because IIB were completely pink whereas IIA were intermediate  8 
between black and pink, appearing as a granular, dark, and pinkish (Behan et  9 
al., 2002).  10 
  11 
2.5 Morphometric Analysis  12 
  13 
The analysis of the fiber type and size was performed with the investigators and  14 
the  staff  blind to  genotype  and training  status.  Samples  were  analysed  using  15 
light microscopy and computer-based planimetry (AxioVision 40 V 4.6.3.0, Carl  16 
Zeiss Imaging Solutions GmbH,  2006-2008).  Tissue sections were viewed using  17 
the 10 x and 20 x objectives and visualized on the monitor. Several still images  18 
for each case were imported into the image analysis package, and morphometric  19 
data on muscle fibres retrieved by means of manual routine using the AxioVision  20 
software. Areas of fibre cross section were recorded. More than 200 fibres were  21 
counted at random on each SDH stained section examined. Based on mATPase  22 
and IHC classification of the three major fiber types, we therefore established a  23 
staining intensity for the SDH-stained slides. Using the ATPase method, almost  24 
100 fibres on average were counted on the pH 9.4 preparations as type I and II  25 
and then a further 100 on the pH 4.6 sections were analyzed as type IIA or IIB.  26 
Using  the  IHC  method,  the  100  fibres  were  counted  and  classified  on  one  27 
preparation as type I, IIA, or IIB. The same 100 fibres were matched in the SDH  28 
preparation. Manual outlining was performed, and the delineation of the fibres  29 
was determined based on the staining intensity and mitochondrial content of the  30 
SDH-stained  slides.  In  order  to  enhance  objectivity  and  to  eliminate  intra- 31 
examiner variation, random sections were also examined by qualified members  32 
of staff (Dr.Ian Montgomery and Mr.David Russel).   33   36 
  1 
2.6 Strength Training  2 
  3 
The subjects took part in a 12 week long training program of the quadriceps of  4 
their non-dominant leg.  The intensity and volume of the training were set to  5 
elicit both strength gains and muscle hypertrophy (Baechle 1994).  The training  6 
ran for 12 weeks to allow muscular adaptations to occur, in particular changes in  7 
the cross sectional area of the muscle fibres. There is a contradiction in the  8 
literature regarding the neural adaptation to exercise. Adaptations during the  9 
first  5  weeks  are  mainly  neural  (Sale,  1988)  with  improvements  in  strength  10 
resulting from the learning effect – the subjects become more familiar with the  11 
apparatus  and  exercise.  During  a  familiarization  session,  each  subject‘s  1- 12 
repetition maximum (1-RM) load for non-dominant leg extension on the training  13 
device (leg extension machine, paramount inc.) was determined. Each training  14 
session consisted of one warm-up set of 10 repetitions at 25 % of 1-RM followed  15 
by 4 sets of 10 repetitions at 70 % 1-RM with 1-minute rest between sets. Each  16 
repetition required one second to lift the weight and one second to lower the  17 
weight.  The  training  was  performed  3·wk
-1  for  12  wk,  that  is,  a  total  of  36  18 
training  sessions  (see  Fig  2.4).  All  training  sessions  were  supervised,  with  19 
continual  verbal  encouragement  given  throughout.  Before  the  training  was  20 
started, the leg extension was set up individually for each subject.  The seat was  21 
set at the correct setting based on subjects‘ anthropometric characteristics; this  22 
was reassured by providing a 2 cm space between the back of the subject‘s knee  23 
and the edge of the seat. The lever for the roller pad was set at the correct  24 
length for the subject – resting on the top of the subject‘s ankle.  The settings  25 
for each subject were recorded. If the subject could not complete 10 repetitions  26 
at the training weight, the load was immediately reduced by 2 increments (each  27 
weight increment was 5 lb (pounds)) on the leg extension and the set of 10 was  28 
completed.  This ensured that each subject completed a total of 40 repetitions  29 
every training session.   Once the subject performed two consecutive training  30 
sessions  (when  they  completed  four  sets  of  ten  reps  without  dropping  the  31 
weight), the load was increased by one increment on the leg extension machine  32 
for the next session.  33   37 
  1 
  2 
2.7 Strength Testing  3 
  4 
Subjects were asked to refrain from exercise and  alcohol intake for 24 hours  5 
prior to testing. Baseline measurements were taken twice within a 7 day period  6 
(at  least  3  days  apart),  and  post-training  measurements  were  taken  once  7 
between  3 and  7  days  after  the  final  training  session.  The  reported  baseline  8 
strength data is the highest values observed on either of the test days.  During  9 
the training period, strength tests of both the trained and untrained leg were  10 
carried out once a week. The highest value from three attempts in each test was  11 
recorded. Prior to initial strength testing, each subject was familiarised with the  12 
testing  protocols  during  a  full  practice  session  to  enhance  reliability  of  13 
measurement  (Kues  at  al.,  1992),  and the  individual  subjects  anthropometric  14 
measurements were stored in the Kin-Com Kinematic Dynamometer (Kin-Com,  15 
Chattanooga, TN). On all test days, testing sessions involved using the Kin-Com  16 
to obtain values for isometric strength at each of the joint angles of 5º, 30º and  17 
60º, and isokinetic strength at an angular velocity of 60ﾰ·sec
-1 and 180ﾰ·sec
-1.  18 
The slower isokinetic angular velocity of 60ﾰ·sec
-1 was tested first in order to  19 
facilitate  motor  learning  prior  to  testing  at  faster  velocities  (Griffin  et  al.,  20 
1987). Each isometric measurement involved at least three practice trials, and  21 
then at least three maximum voluntary contractions (MVC) with at least 30 sec  22 
rest between each. The isokinetic measurement involved at least three practice  23 
trials,  and  then  one  set  of  three  consecutive  repetitions.  The  training  load  24 
produced  from  the  strength  testing  protocol  was  not  designed  to  elicit  any  25 
training effects on the untrained leg that was tested weekly.  For each maximal  26 
trial, subjects were given verbal encouragement and instructed to produce as  27 
much force as possible for at least four seconds (isometric) or throughout the  28 
duration of the contraction (isokinetic).  29   38 
  1 
  2 
Figure 2.3: Kin-Com Kinematic Dynamometer (Kin- 3 
  com,Chattanooga,TN)    4 
  5 
  6 
Figure 2.4: Schematic experimental procedure.  7 
  8 
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2.8. Statistical analysis  2 
Statistical  analysis  was  performed  using  SPSS  (Statistical  Package  for  Social  3 
Sciences) version 15.0 for Windows and Statistica 8.0 (Stat Soft Inc., 2007) for  4 
Windows. For the purpose of the study, the data set were checked for outliers,  5 
which were defined by SPSS. Outliers were characterized by SPSS as lowest and  6 
highest extreme values, but were not excluded from the analysis, as they were  7 
considered important for the data set. Data were checked for normality using  8 
the  Shapiro-Wilk  tests,  as  it  is  supported  by  many  authors  to  be  more  9 
appropriate for a check of non-normality in small to medium samples (Shapiro  10 
and Wilk, 1965; Royston, 1982a, 1982b, 1995; Conover, 1999). Parametric and  11 
non-parametric tests were used throughout the analysis. Paired t-tests or Mann- 12 
Whitney  tests  where  appropriate  were  used  to  compare  the  effect  of  the  13 
strength training program both for untrained and trained leg, the changes in the  14 
average cross-sectional area, and the percentage of the muscle fiber types pre  15 
and  post,  as  well  as  the  circulating  ACE  activity  pre  and  post.  Linear  trend  16 
analysis  was  performed  to  exclude  the  confounding  effects  of  weight,  BMI,  17 
physical activity levels etc. Two-way ANOVA for repeated measures were used to  18 
assess  the  training  responses  over  times  and  post-hoc  analysis  included  19 
Bonferroni tests. In cases where significance was identified, the difference for  20 
the factor was further determined for each time point using paired-sample t- 21 
tests. The Pearson product-moment correlation coefficient (r) or Spearman‘s rho  22 
was  used  to  investigate  the  relationship  between  baseline  ACE  activity  and  23 
baseline  muscle  strength,  between  ACE  activity,  fiber  types  and  fiber  cross- 24 
sectional  area,  ACE  activity  and  ACE  genotype,  ACE  genotype  and  baseline  25 
characteristics and on the adaptations to strength training. The effects of ACE  26 
genotype on baseline characteristics (with baseline body mass, stature, BMI and  27 
activity  levels  as  covariates),  on  the  adaptations  to  strength  training  (with  28 
baseline body mass, stature, BMI, and strength and activity levels as covariates)  29 
and  on  muscle  morphology  (with  strength  and  physical  activity  levels  as  30 
covariates) were assessed for linear trend using General Linear Model Analysis.  31 
The partial eta squared effect size statistic (which indicates the proportion of  32 
the effect and error variance that is attributable to the effect) was obtained  33 
during General Linear Model Analysis (GLM), as well as the observed power (p).  34   40 
Data is expressed as mean ± standard error of the mean (SEM) unless otherwise  1 
stated. The accepted level of significance was set at P < 0.05 for all statistical  2 
tests.  3 
  4 
3. Results   5 
  6 
3.1 Subject characteristics  7 
All 18 subjects completed the study according to the protocol described in the  8 
methods  section.  Their  mean  ±  STDV  baseline  characteristics  are  depicted  in  9 
Table  3.1.  Changes  in  circulating  ACE  activity  are  shown  in  Table  3.1.i.  No  10 
significant  differences  were  found  between  the  two  groups  (II  and  DD)  as  11 
assessed by general linear model analysis and independent t-tests with the level  12 
of significance set at P = 0.05.  13 
Table 3.1: Mean (± STDV) physical characteristics of the total sample and by ACE  14 
ID genotype.  15 
    
DD   II   DD  + II  
 
      P  
      (n=7)  (n=11)  (n=18)  (DD vs II) 
                         
Weight (kg)     75.1 ± 10.22  76.9 ± 7.3  76.2 ± 8.2  0.67 
                 
Height (cm)  179 ± 0.08  179 ± 0.08  179 ± 0.1  0.92 
                 
BMI (kg/m
2)  23.1 ± 1.3  23.8 ± 1.16  23.6 ± 1.4  0.29 
                 
Physical     
activity levels 
(h/week)  11 ± 3.1  8.1 ± 3.5  9.2 ± 3.5  0.08 
                 
   Age (y)  23.1 ± 3.2  22.8 ± 2.9  22.9 ± 2.8  0.92 
  16 
There were no significant differences in physical characteristics among the ACE ID  17 
genotypes. I, insertion allele; D, deletion allele; BMI,body mass index, P < 0.05.  18 
19   41 
Table 3.1.i: Changes in circulating ACE activity from pre to post-training (mean ±  1 
SEM).    2 
    
DD   II   DD  + II  
 
      P  
      (n=7)  (n=11)  (n=18)  (DD vs II) 
                         
Circulating ACE 
activity (nmol 
His-Leu/min/mL 
)             
   Pre      39.7 ± 40  40.5 ± 3.30  40.2 ± 2.5  0.89 
   Post  41.9 ± 3.7  35.5 ± 4.30      38.1 ± 3.0  0.30 
P (Pre vs Post)  P = 0.10  P = 0.26  P = 0.41   
                          
                          
There were no significant differences in circulating ACE activity among the ACE ID  3 
genotypes.ACE, angiotensin converting enzyme; I, insertion allele; D, deletion allele; P  4 
< 0.05.  5 
  6 
  7 
  8 
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3.3 Muscle fiber average cross-sectional area changes  2 
  3 
A significant difference was noticed in the average cross-sectional area (AVECSA)  4 
of Type IIA between pre and post: (4264 ± 224 μm² pre-training, 4774 ± 226.7  5 
μm² post-training, t(17)= -2.261, P = 0.02), as well as Type IIB AVECSA: (3996 ±  6 
170 μm² pre-training,  4463 ± 217 μm² post-training, t (17) = -2.142, P = 0.04) ).  7 
On  the  contrary,  the  change  in  the  AVECSA  of  Type  I  fibres  wasn‘t  deemed  8 
significant (3583 ± 284 μm²  pre-training, 3902 ± 250 μm² post-training, t (17) = - 9 
1.664, P = 0.11) when data was assessed regardless genotype (see also Table  10 
3.2).  When  the  data was  assessed  for  II  and  DD  individuals  separately,  for  II  11 
genotype (n = 11), AVECSA of Type I increased significantly (3345 ± 207 μm² pre- 12 
training, 3988 ± 239 μm² post-training, t (10) = -3.063, P = 0.01)(see also Table  13 
3.2). For DD genotype (n = 7), a significant increase in AVECSA of Type IIA fibres  14 
(4070 ± 506 μm² pre-training,  4674 ± 399 μm² post-training, t (6) = -2.999, P =  15 
0.02),  as  shown  in  Table  3.2.  Two-way  analysis  of  variance  for  repeated  16 
measures did not show any differences in the II and DD response to the training  17 
program. More specific, ACE genotype did not affect the AVECSA of Type I fibers  18 
(F (1, 32) = 0.243, P = 0.62), as well as the AVECSA of Type IIA fibers (F (1, 32) =  19 
0.512, P = 0.48) and the AVECSA of Type IIB fibers (F (1, 32) = 0.049, P = 0.84)  20 
(see also Table 3.2)  21 
  22 
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Table 3.2: Mean (±SEM) muscle fiber type and average cross-sectional area at baseline  1 
and  post–resistance  training  in  the  total  sample  and  by  ACE  II/DD  genotype.  The  2 
accepted level of significance was P < 0.05.  Asterisk (*) indicates significant difference  3 
from pre-training values.  4 
      II GENOTYPE  DD GENOTYPE  DD vs II  DD + II 
      (n=11)  (n=7)  (n=18)  (n=18) 
Proportion of fibre types 
(%)                         
                   
Type I  Pre  50.2 ± 1.5  50.8 ± 3    50.4 ± 1.4 
                   
  Post  48.1 ± 1.6     52.9 ± 4.6         49.9 ± 2 
                   
  Δ  2.1 ± 2.2       2.1 ± 2.9        P = 0.31     0.4 ± 1.7 
                   
Type 
IIA  Pre     28 ± 1.1     26.2 ± 1.8    27.3 ± 0.9 
                   
  Post  28.2 ± 1.2     25.9 ± 3.8    27.4 ± 1.6 
                   
  Δ  0.2 ± 1.7    0.3 ± 3        P = 0.31    0.15 ± 1.5 
                   
Type 
IIB  Pre  21.9 ± 1.1      22.9 ± 2.3    22.3 ± 1.1 
                   
  Post  23.6 ± 1.6      21.1 ± 1.6    22.6 ± 1.2 
                   
   Δ  1.7 ± 1.8        1.8 ± 1.7        P = 0.65     0.33 ± 1.3 
Average Cross Sectional 
Area per fibre type (μm²)                      
Type I  Pre  3345 ± 207  3955 ± 660    3582  ± 283 
                   
  Post  3988 ± 239*  3765 ± 549    3901 ± 250 
                   
  Δ     643 ± 210    190 ± 285        P = 0.62    319 ± 191 
  Δ %        22 ± 8     1 ± 8.5      13 ± 6.3 
Type 
IIA  Pre  4386 ± 194  4070 ± 506    4263 ± 224 
  Post  4837 ± 284  4674 ± 399*    4774 ± 226* 
                   
  Δ    451 ± 321      604 ± 201        P = 0.48    511 ± 207  
  Δ %     12 ± 8.9     21 ± 10.5      16 ± 6.6 
Type 
IIB  Pre  3972 ± 174  4033 ± 363    3996 ± 170 
                   
  Post  4533 ± 278  4353 ± 369    4463 ± 216* 
                   
   Δ    561 ± 318   320 ± 270        P = 0.84     466 ± 217  
    Δ % 
   16 ± 9.4 
  
  10 ± 8.1 
  
  
  
      14 ± 6.4 
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Muscle Strength for Untrained and Trained Leg  2 
3.4 Muscle strength and force production  3 
Muscle strength was measured as force and torque production during maximal  4 
isometric  and  isokinetic  knee  extensions  respectively  on  an  isokinetic  5 
dynamometer.  Baseline  measurements  (pre-training)  indicated  no  significant  6 
differences between the untrained and trained leg. After the 12 week strength  7 
training program of the trained leg, the increase in force production is obvious,  8 
with  significant  differences  from  the  pre-training  status,  as  well  as  from  the  9 
untrained  leg  force  production  as  assessed  from  student‘s  paired  t-tests.  A  10 
significant increase (680 ± 30 N pre-training, 793 ± 40.38 N (SEM) post-training, P  11 
= 0.001) was noticed for the 5 º isometric angle of the trained leg. The mean  12 
force of the trained leg  at 30 º isometric angle also increased (759 ± 36 N pre- 13 
training, 956 ±  36 N (SEM) post-training,  P = 0.00), and so did  60 º isometric  14 
angle (444 ± 17 N pre-training, 566 ±  20 N (SEM), P = 0.00) and 60 º/s isokinetic  15 
angle (605 ± 20 N pre-training, 676 ± 19 (SEM) post-training, P = 0.002 ). 180 º/s  16 
isokinetic angles in both legs deemed no significant results (see table 3.3).   17 
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  1 
Degrees  Leg Dominance  Pre  Post 
5° 
Untrained  683  ± 32  678 ± 37  
Δ %      -1 ± 2 
Δ      -5 ± 17 
Trained  680  ±  30  793 ± 40 * †  
  Δ %      18 ± 4 
   Δ       
  
114 ± 28 
30° 
Untrained  736  ± 34  741 ± 32 
Δ %      1 ± 2 
Δ      5 ±17 
Trained  759 ± 36  956 ± 36 *†  
  Δ %      28 ± 3 
   Δ       
  
197 ± 22 
  Untrained  449  ± 17  462  ± 17 
  Δ %      3 ± 2 
60°  Δ      13 ± 10 
  Trained  444 ± 17  566 ± 20 *†  
  Δ %      30 ± 6 
   Δ       
  
122 ± 22 
  Untrained  599  ± 25  567 ± 21 * 
  Δ %      -5 ± 2 
60°/sec  Δ      -32 ± 13 
  Trained  605 ± 20  676 ± 19 *†  
  Δ %      13 ± 4 
   Δ       
  
71 ± 19 
  Untrained  505 ± 16  482 ± 17 
  Δ %      -4 ± 3 
180°/sec  Δ      -22 ± 12 
  Trained  524 ± 13  532 ± 13†  
  Δ %      8 ± 12 
   Δ       
  
2 ± 2 
                 
Table 3.3: Mean ± SEM of the muscle strength of all subjects pre-and post-training in  2 
all angles, untrained and trained leg values are also included. Asterisk (*) indicates  3 
significance towards baseline (pre) values (P < 0.05), dagger (†) indicates significance  4 
towards the values for the untrained leg, (N) = Newton, n = 18, Δ is the difference  5 
between pre and post, Δ % is the percentage of difference between post and pre, P <  6 
0.05 for all tests.  7   46 
  1 
When the data is presented genotype-dependant, we can see that there were no  2 
significant differences between gains in force for II and DD subjects, except from  3 
the isometric 60ﾰ angle, where a significant difference were detected between  4 
the gain in force of the trained leg post-training in favor of the DD individuals (as  5 
assessed with two-way ANOVA for repeated measures).  Trained leg presented  6 
greater  strength  gains  compared  to  the  untrained  leg  in  all  angles  for  both  7 
genotypes,  with  significant  differences  between  pre  and  post  as  assessed  by  8 
Student‘s paired t-test (see table 3.4).  9 
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  1 
  2 
Degrees  Leg Dominance     Genotype    
  
  
DD   II 
  Pre  Post  Pre  Post 
5°  Untrained  678 ± 32  658 ± 53  687 ± 50  692 ± 53 
  Δ %      -4 ± 5    1 ± 2 
  Δ      -20 ± 34    5 ± 19 
  Trained  702 ± 34  798 ± 11 *‡  667 ± 45  791 ± 67 ‡ 
  Δ %      15 ± 6    19 ± 6 
  Δ      97 ± 34    124 ± 42 
30°  Untrained  741 ± 30  728 ± 41  734 ± 54  750 ± 48 
  Δ %      -2 ± 4    3 ± 3 
  Δ      -13± 33    16 ± 19 
  Trained  831 ± 33 ‡  1017 ± 38 *‡  714 ± 52  918 ± 52 *‡ 
  Δ %      23 ± 4    31 ± 5 
  Δ      187 ± 28    204 ± 31 
60°  Untrained  461 ± 23  465 ± 22  443 ± 24  460 ± 26 
  Δ %      1 ± 2    4 ± 3 
  Δ      4 ± 11    17 ± 15 
  Trained  473 ± 25  617 ± 25 *‡†  427 ± 24  534 ± 27 *‡ 
  Δ %      32 ± 8    28 ± 9 
  Δ      144  ± 32    108 ± 30 
60°/sec  Untrained  626 ± 40  594 ± 37  582 ± 34  551 ± 26 
  Δ %      -5 ± 4    -4 ± 3 
  Δ      -32 ± 19    -31 ± 19 
  Trained  618 ± 37  699 ± 23 ‡  597 ± 25  662 ± 28 *‡ 
  Δ %      16 ± 9    12 ± 4 
  Δ      81 ± 38    65 ± 21 
180°/sec  Untrained  510 ± 15  483 ± 25  502 ± 26  483 ± 24 
  Δ %      -5 ± 4    -3 ± 3 
  Δ      -27 ± 23    -19 ± 15 
  Trained  531 ± 15  530 ± 22  520 ± 20  532 ± 18 ‡ 
  Δ %      0 ± 3    3 ± 4 
  Δ      -1± 15    13 ± 17 
                    
  3 
Table 3.4: Changes in strength output of the untrained and trained leg by  4 
genotype. Data presented as mean ± SEM , double dagger (‡) indicates significance  5 
trained leg vs untrained leg, dagger (†) indicates significance towards II genotype,  6 
asterisk (*) indicates significance pre vs post,  Δ is the difference between pre and  7 
post, Δ % is the percentage of difference between post and pre. P < 0.05 for all tests.  8   48 
Correlations  1 
For those completing the training program, baseline circulating ACE activity did  2 
not  alter  with  training  (see  Table  3.1).  In  addition  to  this,  there  were  no  3 
significant  differences  between  pre-  and  post-strength  training  levels  of  4 
circulating ACE activity when total sample was taken into account (DD+II, n =  5 
18), or when DD and II were tested separately (see Table 3.1). As shown in figure  6 
3.1  and  figure  3.2,  baseline  strength  measures  correlated  significantly  with  7 
circulating  ACE  activity.  This  applied  mainly  to  isometric  strength  of  the  8 
untrained leg at 5ﾰ (683 ± 32.3 N) (r = 0.46, P = 0.05) (Fig.3.1), and isokinetic at  9 
180ﾰ/sec  of  the  untrained  leg  (505  ±  16.3  N)  (r  =  0.52,  P  =  0.03)  (Fig.3.2).  10 
Weaker correlations were found between circulating ACE activity pre and post  11 
and other degrees and velocities, although not significant (data shown in the  12 
appendix).  Circulating  ACE  activity  measured  prior  to  the  strength  training,  13 
correlated positively with weight and height of the subjects (r = 0.62, P = 0.01  14 
and  r=  0.65,  P=  0.01  respectively).  Physical  activity  levels  of  the  subjects  15 
correlated with the isometric strength at 30ﾰ of the trained leg (r= 0.49, P =  16 
0.03, data also shown in the appendix). Average cross-sectional area of type IIA  17 
and IIB fibers post-training, correlated positively and significantly with the post- 18 
training strength output of the trained leg at 60ﾰ/sec (r = 0.56, P = 0.01 and r =  19 
0.59, P = 0.01 respectively), but there was no correlation between the AVECSA  20 
of all fiber types or percentages and the circulating ACE activity pre-or post- 21 
training (data shown in the appendix). The second correlation persisted after the  22 
data were presented as force per kilogram of body mass (r = 0.49, P = 0.03).  23 
When the data were processed as force production per kg of body mass, all the  24 
significant observations made above (significant correlations) did not persist and  25 
became  non-significant.  In  addition  to  this,  spurious  correlations  without  any  26 
known biological reason appeared throughout the correlation tables (data shown  27 
in the appendix). The power limitation of the study prevents us from attributing  28 
those correlations to an actual relationship between the variables.  29 
  30 
  31   49 
R² = 0.22
300
500
700
900
1100
10 20 30 40 50 60 70
DD
II
Baseline Circulating ACE Activity (nmol His-Leu/min/mL)
I
s
o
m
e
t
r
i
c
 
S
t
r
e
n
g
t
h
 
a
t
 
5
°
(
N
)
1 
  2 
  3 
Figure 3.1: Relationship between pre-training circulating ACE activity (nmol His- 4 
Leu/min/mL)  and  isometric  strength  (baseline  measurements)  at  5ﾰof  the  5 
untrained leg, n = 18,  r = 0.46,  P = 0.05  as assessed by Pearson‘s  product- 6 
moment  coefficient  correlation.  Solid  line:  best-fit  linear  regression  line.  7   50 
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Figure 3.2: Relationship between pre-training circulating ACE activity (nmol His- 3 
Leu/min/mL) and isokinetic torque (baseline  measurements) at 180ﾰ/s of the  4 
untrained leg,  n = 18, r = 0.52 , P = 0.03 as assessed by Pearson‘s product- 5 
moment coefficient correlation. Solid line: best-fit linear regression line.  6 
  7 
3.5 Main effects and significant interactions  8 
Two way analysis of variance for repeated measures, revealed some significant  9 
effects and interactions. Specifically, for isometric force at 30º, the effect of leg  10 
dominance was F (1, 64) = 13.919,  P = 0.01, but genotype was not affecting  11 
strength (F (1, 64) = 2.010, P = 0.16), see also figure 3.3.  12 
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Figure 3.3: The effect of the leg dominance on isometric force in 30º angle pre- 2 
and  post-training,  the  asterisk  (*)  indicates  significance  towards  pre-training,  3 
dagger (†) indicates significance towards untrained leg. Data presented as mean,  4 
vertical bars indicating confidence intervals (95%).  5 
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On the contrary, in 60 º post-training,  a significant effect of the genotype was  1 
revealed in favour of the DD individuals  on the trained leg F(1,64) = 4.242 , P =  2 
0.043, observed power = 0.53 ,partial eta squared = 0.062, see also figure 3.4).  3 
The effect persisted after adjustment for weight, but when it was adjusted for  4 
body mass index and physical activity, the results became non significant (F (1,  5 
63) = 3.13391, P = 0.08, partial eta squared = 0.047, observed power = 0.41) and  6 
F (1, 63) = 3.1628, P = 0.08, partial eta squared = 0.048, observed power = 0.42  7 
respectively).  8 
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Figure 3.4: The effect of the leg dominance on isometric force pre- and post- 11 
training in 60º angle. Asterisk (*) indicates significant difference from baseline  12 
(pre), dagger (†) indicates significance towards untrained leg, double dagger (‡)  13 
indicates significance towards II genotype. Data presented as mean, vertical bars  14 
indicating confidence intervals (95 %), level of significance set at P < 0.05.  15 
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  1 
Trained leg overtook untrained (F (1,448) = 86.68, P = 0.00) in many time points  2 
during  the  12  week  strength  training  program  (see  figures  3.5  and  3.6).  3 
Isokinetic velocities of joint movement (60º/sec, and 180º/sec) both were not  4 
affected  by  genotype,  but  trained  leg  gained  significantly  higher  force  than  5 
untrained leg at 60º/sec (F(1,448) = 58.99, P = 0.00) and  (F (1,448)=13.64, P =  6 
0.01) at 180º/sec.   7 
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Figure 3.5: Data is mean ± SEM for all subjects (n = 18) for untrained  and  9 
trained (square) leg through 12 weeks of strength training in 30º angle. Asterisk  10 
(*) indicates significantly different from baseline measurements (pre). Dagger (†)  11 
indicates trained leg significantly different from untrained, P<0.05.  12 
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Figure 3.6: Data expressed as mean ± SEM of 18 observations (n = 18) in 60º  2 
isometric  angle  through  12  weeks  of  training.  Asterisk  indicates  significantly  3 
different  from  baseline  measurements  (pre).  Dagger  (†)  indicates  trained  leg  4 
(black circle) significantly different from untrained leg (black square), double  5 
dagger (‡) indicates significance towards II genotype, P < 0.05.  6 
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For the isokinetic velocities of 60ﾰ/sec and 180ﾰ/sec, no significant effect of  8 
genotype was detected (F (1, 64) = 2.558, P = 0.11 and F (1, 64) = 0.063, P =  9 
0.80 respectively), even when the data was presented per kg of body mass.  10 
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4. Discussion  2 
  3 
The aim of this study was to evaluate the association of ACE I/D polymorphism  4 
and  circulating  ACE  activity  with  quadriceps  muscle  function  and  contractile  5 
properties,  as  well  as  with  changes  in  skeletal  muscle  fiber  type  or  cross- 6 
sectional area in response to strength training programme. It was hypothesized  7 
that  baseline  strength  would  be  higher  in  homozygotes  for  the  D  allele,  8 
compared to homozygotes for the I allele. Our study did not find any association  9 
between  baseline  strength  measurements  and  ACE  gene,  but  the  association  10 
found is after the training intervention and thus adaptation to strength training.   11 
It  was  also  hypothesized  that  there  would  be  a  difference  in  the  strength  12 
development between the homozygotes for the I allele carriers and the D allele  13 
carried, and based on the existing literature, homozygosity for the D allele will  14 
be favored. Isometric force at 60º post-training revealed a significant effect of  15 
the genotype, in favour of the DD individuals, on the non-dominant leg F (1, 64)  16 
= 4.242, P = 0.04, observed power = 0.53, partial eta squared = 0.062). The  17 
effect persisted after adjustment for weight, but when it was adjusted for body  18 
mass index and physical activity (assessed by questionnaires), the effect became  19 
non-significant  (F  (1,  63)  =  3.13391,  P  =  0.08,  partial  eta  squared  =  0.047,  20 
observed power = 0.41); and F (1, 63) = 3.1628, P = 0.08, partial eta squared =  21 
0.048, observed power = 0.42, respectively). Last, it was hypothesized that   22 
Type II fibres of homozygotes for the D allele will show more hypertrophy 11  23 
than  I  homozygotes  for  the  I  allele  in  response  to  a  strength  training  12  24 
programme. The average cross-sectional area (AVECSA) of Type IIA fibres for the  25 
DD individuals increased significantly post-training (4070 ± 506 μm² pre-training,  26 
4674 ± 399 μm² post-training, t (6) = -2.999, P = 0.02) and so did the AVECSA of  27 
the Type I fibers of II individuals (3345 ± 207 μm² pre-training, 3988 ± 239 μm²  28 
post-training, t (10) = -3.063, P = 0.01, see Results section for all the above).  29 
The latter finding shows that the strength training programme applied resulted  30 
in muscle hypertrophy, but the changes in AVECSA were not genotype-related as  31 
two way analysis of variance for repeated measures revealed (see Table 3.2).  32 
  33 
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In  the  present  study  an  association  was  detected  between  circulating  ACE  1 
activity  and  isometric/isokinetic  angles/velocities,  with  the  strongest  2 
correlations depicted in figures 3.1 and 3.2. Those findings come in line with the  3 
results reported from Williams et al., (2005), who found a relationship  between  4 
the isokinetic velocity of 60ﾰ (1.05 rad sec
-1) and pre-training circulating ACE  5 
activity,  in  a  total  of  81  subjects.  Pearson‘s  r  was  r  =  0.375,  P  <  0.00050  6 
(Williams  et  al.,  2005).  In  our  study,  a  significant  correlation  was  noticed  7 
between the isometric strength of the untrained leg at 5ﾰ and circulating ACE  8 
activity, in a total of 18 subjects (Pearson‘s r = 0.46, P = 0.05) and isokinetic  9 
strength at 180ﾰ/sec of the untrained leg (Pearson‘s r = 0.52,  P = 0.03), see  10 
figures  3.1  and  3.2  respectively.  Hopkinson  et  al.,  (2004)  also  found  that  in  11 
patients  with  COPD  (chronic  obstructive  pulmonary  disease)  strength  results  12 
were associated with the D allele of the ACE gene. On the contrary, there are  13 
many studies that do not find an actual relationship between circulating ACE  14 
activity and strength gains. Folland et al., (2000) for example, did not find any  15 
association between pretraining strength of quadriceps and ACE gene, but one  16 
could claim that this was due to the fact that he didn‘t measure circulating ACE  17 
activity  alone  but  he  rather  used  an  indirect  genetic  marker,  such  as  ACE  18 
genotype.  Moreover,  this  study  didn‘t  have  the  power  to  detect  such  an  19 
association as Williams and colleagues (2005) indicate. In line with this, Thomis  20 
et al., failed to prove the same association in the upper body muscles though  21 
(elbow flexors). Thomis et al., (2004) found no evidence for an  ACE D allele  22 
effect on skeletal muscle response to functional overload.  In the present study,  23 
study, circulating ACE activity was measured alone, although the correlations  24 
found might be correlations occurred by chance, as neither our study is powered  25 
to detect any significant effects. According to power calculations, 46 subjects at  26 
least would be sufficient if a power of 80% of detecting a meaningful correlation  27 
is desired. More recently, Charbonneau et al., (2008) on a large study conducted  28 
on both men and women (although underpowered for sex-related associations),  29 
and based on the existent literature, concluded that there was an association  30 
between  the  ACE  genotype  and  baseline  strength  measurements,  but  no  31 
associations  were  observed  for  the  1  RM  or  the  adaptations  to  the  strength  32 
training for either men or women. Subjects in the previous study had a mean age  33 
of 62 years old (between 50 and 85); a factor which might possibly set a limit to  34 
the  findings  of  this  study  as  far  as  the  generation  of  force  is  concerned.  In  35   57 
addition  to  that,  ageing  is  associated  with  considerable  strength  loss  and  1 
declining muscle mass (Kallman et al., 1990) along with mobility impairments  2 
and, especially in women after menopause, a notable loss of muscle mass when  3 
the hormonal balance is changed. The decline in men starts below the age of 70,  4 
and by 90 years old, there is a reduction in muscle mass of a magnitude of 30 %  5 
(Grimby  and  Saltin,  1983).  Our  study  did  not  find  any  association  between  6 
baseline strength measurements and ACE gene, but the association found is after  7 
the training intervention and thus adaptation to strength training. A recent study  8 
from Day and his colleagues (2007) also found no correlation between circulating  9 
ACE activity and VO2max or mechanical efficiency in 62 untrained women of a  10 
sedentary background Day et al., 2007). In a very recent study, McCauley and his  11 
colleagues (2009) examined the relationship between ACE I/D and ACTN3 R/X  12 
polymorphisms,  with  muscular  strength  at  high  velocities.  Seventy-nine  13 
recreationally  active  but  non-strength-trained  males  participated,  and  14 
measurements were taken in two occasions, isometrically (73 °, 1.27 rad) and  15 
isokinetically (30 ﾰ/sec, 90 ﾰ/sec and 240ﾰ /sec,which is 0.52, 1.57 and 4.19  16 
rad/sec respectively). The characteristics of the subjects did not differ from our  17 
cohort, and the methods used for the assessment of the various parameters were  18 
similar  to  our  study.  Those  two  polymorphisms  didn‘t  influence  muscular  19 
strength at high velocities or the time course of the twitch response, nor there  20 
any association of circulating ACE activity with any measure of muscle function,  21 
indicating that the magnitude of the effect is not sufficient for associations of  22 
this kind (McCauley et al., 2009). In addition to the power problems that gene  23 
association studies present, regarding the ACE gene, a large inconsistency in the  24 
literature  is  noticed,  fact  that  makes  comparison  among  studies  particularly  25 
difficult. Charbonneau and his colleagues (Charbonneau et al., 2008) adopt a  26 
very skeptical attitude towards whether ACE is a gene with strong relevance for  27 
skeletal  muscle  phenotypes,  because  of  the  problems  mentioned  above.  28 
Differences  in  methodology  between  the  studies  reduce  significantly  29 
reproducibility and prevent replication of data in an independent cohort.  30 
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One would expect that since circulating ACE activity is associated with strength,  1 
the rationale suggests that the genotype will be related in a similar way. In the  2 
present study, probably for methodological reasons such as the sample size or  3 
the differences between the number of individuals in each group, circulating  4 
ACE activity was not associated with ACE genotype (see Results, Table 3).The  5 
two groups (II and DD) presented similar values. Williams and colleagues (2005)  6 
for example found that 4-7 % of the variation in strength could be attributed to  7 
ACE  genotype.  Here,  a  methodological  issue  arises:  many  previous  studies  8 
(Charbonneau et al., 2008, Thomis et al., 2004, Folland et al., 2000, Pescatello  9 
et al., 2006, Karjalainen et al., 1999, Taylor et al., 1999, Rankinen et al., 2000,  10 
Zhao  et  al.,  2003)  were  looking  at  the  genetic  marker  alone  (ACE  II/DD  11 
polymorphism)  instead  of  looking  directly  to  ACE  activity.  ACE  genotype  is  a  12 
categorical  variable  and  thus  cannot  be  quantified  in  a  meaningful  way.  13 
Montgomery  et  al.,  (2002)  in  a  recent  review  article,  explored  whether  it  is  14 
better to use phenotype or genotype as a tool for investigating the role of ACE.  15 
It was suggested that, because much of the ACE activity within the circulation  16 
cannot be explained solely by an individual‘s ACE ID polymorphism genotype,   17 
ACE phenotype, and not merely the genotype, is associated with many diseases.  18 
It  is  therefore  possible  that  the  circulating  ACE  activity  is  more  strongly  19 
associated with endurance performance than the ID polymorphism within this  20 
gene (Montgomery et.al, 2002). The problem, as mentioned in the paper from  21 
Williams et al., (2005) with using a categorical variable in order to establish a  22 
correlation of a desirable effect, is that the number of the subjects required is  23 
almost ten times the number of participants needed when a continuous variable  24 
is examined. For example, in the aforementioned study (Williams et al., 2005),  25 
interim  power  calculations  showed  that  more  than  300  subjects  would  be  26 
required to establish statistical significance for correlations of the magnitudes  27 
that  were  observed,  and  moreover,  ―the  added  power  of  seeking  association  28 
with a continuous variable (ACE activity) rather than categorical surrogate of  29 
ACE activity (ACE genotype) suggests that a sample size of much greater than  30 
300 would be required to identify a very weak effect of ACE genotype on the  31 
training response‖ (Williams et al., 2005).  32 
There  is  also  another  reason  that  supports  this  view.  In  the  present  study,  33 
circulating ACE activity was identified by drawing blood samples 1 week before  34 
and one week after the 12 week training program as it is depicted in figure 2.4.  35   59 
For those completing the training program,  baseline ACE activity didn‘t alter  1 
significantly with training (see Results section, chapter 3.1). This finding comes  2 
in line with past studies that identified this stability in circulating ACE activity  3 
over time. Day et al., (2004) for instance examined the acute effects of aerobic  4 
exercise, resistance exercise and glucose ingestion on circulating ACE activity  5 
and  he  found  that  pre-intervention  ACE  activity  remained  remarkably  stable  6 
across all testing days, and moreover there was no significant change in ACE  7 
activity  following  all  the  interventions.  Back  in  1984,  Dux  and  his  colleagues  8 
(1984) found that if measured in a specific subject, plasma ACE level remains  9 
unchanged  over  time.  The  findings  of  this  study  compliment  the  results  of  10 
previous studies and hence support the use of phenotype (plasma ACE activity)  11 
over genotype when these kinds of associations are desired.   12 
ACE is a key component of   RAS (Renin-Angiotensin System) and converts ANGI  13 
to ANGII (Bernstein et al., 1989). Engeli (1999) first mentioned the existence and  14 
function of a local RAS system in various tissues, including the cardiac, nervous  15 
and skeletal muscle tissue. Those systems have been found to be equipped with  16 
all the necessary components for the synthesis of ANGII (review by Jones and  17 
Woods, 2003), which led Lavoie to explore if there is a paracrine action of the  18 
RAS (Lavoie and Sigmund, 2003). ACE genotype on the other hand, is proved to  19 
influence both circulating and tissue ACE activity, as several studies have proven  20 
(  Rigat  et  al.,  1990;  Danser  et  al.,  1995;  Martin  et  al.,  2006).  Hence,  the  21 
strength  gains,  or  better,  the  differences  in  strength  gain  between  the  22 
genotypes as they are shown in chapters 3.4 and 3.5 in the results section, can  23 
be  explained  via  two  possible  mechanisms:  plasma  ACE  activity  and  an  24 
autonomous skeletal muscle RAS system. ACE dependant synthesis of ANGII may  25 
also induce differences in muscle size. As proved by previous studies, ANGII is a  26 
possible  factor  that  affects  growth  in  cardiac  muscle  cells.  Gordon  and  27 
colleagues  (2001),  in  a  double  experiment  they  conducted,  found  that  28 
angiotensin2  is  necessary  for  the  optimal  overload-induced  hypertrophy  of  29 
skeletal muscle cells as well.  The mechanisms by which this is mediated are  30 
currently  unknown.  ANGII  may  act  directly  on  the  skeletal  muscle  cells,  or  31 
indirectly  act  through  the  simulation  of  adjacent  fibroblasts  or  capillary  32 
angiogenesis  (Gordon  et  al.,  2001).  Jones  and  Woods  (2003)  propose  several  33 
potential mechanisms in an extensive review on how skeletal muscle RAS may  34 
affect  performance.  There  is  a  notion  that  ANGII  may  be  important  in  the  35   60 
redirection of blood flow from type I fibers to type II fibers (Rattigan, Dora,  1 
Tong, & Clark, 1996, cited in Jones and Woods, 2003), that are favored in power  2 
performance and strength training. If ANGII is infused into rat hindlimbs, the  3 
contraction-induced oxygen uptake and the tension during tetanic stimulation  4 
increases (Rattigan et al., 1996, cited in Jones and Woods, 2003). Thus, when  5 
ANGII production is greater, muscle contraction for maximal power is facilitated,  6 
with a potential detrimental effect on efficiency and endurance. In the present  7 
study,  DD  allele  carriers  were  not  associated  with  elevated  circulating  ACE  8 
activity (see Table 3.1 ) compared to the II individuals, but as it was shown in  9 
the results section, DD individuals showed hypertrophy in type IIA fibers (see  10 
table 3.2), although not significantly different from the II individuals in the same  11 
type of fibers. In the same review (Jones and Woods, 2003), ANGII is presented  12 
as a factor that can possibly promote sympathetic transmission by amplifying the  13 
release of noradrenaline from the peripheral sympathetic nerve terminals and  14 
the central nervous system (Story & Ziogas, 1987; Saxena, 1992, as quoted by  15 
Jones and Woods, 2003).  16 
  17 
Another  possible  explanation  of  the  association  of  strength  with  ACE  activity  18 
might be alterations noted in the types of the muscle fibres. It is well known  19 
that the production of mechanical force is well dependent on muscle fiber type.  20 
Types II fibres (type IIA and type IIB) produce greater forces per contractile unit  21 
when  strength/resistance  training  is  applied.  The  increased  muscle  cross- 22 
sectional  area  is  mainly  brought  about  by  hypertrophy  of  individual  muscle  23 
fibres. There is a greater increase in the area of fast twitch fibres compared to  24 
slow  twitch  fibres.  Mitochondrial  volume  density  decreases  in  proportion  to  25 
muscle  hypertrophy  in  response  to  training  (Tesch,  1998).  It  is  generally  26 
accepted that strength training does not induce neofibrogenesis. Zhang and his  27 
colleagues (2003) reported that Japanese individuals carrying the I allele had a  28 
greater proportion of slow-twitch fibers while the D allele carriers had a greater  29 
proportion of fast twitch fibres. Muscle fibres in this study (Zhang et al., 2003)  30 
were  classified  based  on  their  histochemical  staining  for  myosin  adenosine  31 
triphosphatase (mATPase) activity. For ACE II genotype, the proportion of fibres  32 
was as following: type I 59.4 %, type IIA 15.2% and type IIB 25.5%, whereas for  33 
the ACE DD allele, type I fibres were 19.6%, type IIA 29.6 % and type IIB 50.9%  34 
(Zhang et al., 2003). In this study, there was no training intervention, and the  35   61 
subjects‘  characteristics  were  similar  to  our  study;  healthy  young  males  1 
recruited from the University student and staff and were not participating in any  2 
specific  training.  Although,  our  study  is  underpowered  to  detect  any  3 
significance,  Zhang  recruited  41  subjects  and  still  this  study  is  considered  4 
underpowered  (Zhang  et  al.,  2003).  The  aforementioned  study  supports  the  5 
notion that the D allele may influence skeletal muscle function from the aspect  6 
of strength/power at high velocities.  However, Akhmetov et al., (2006), in a  7 
contradictory study on Russian individuals discovered that D allele carriers had a  8 
bigger proportion of slow twitch fibers (Akhmetov et al., 2006). Our study failed  9 
to prove any association of this kind, although the previously mentioned studies  10 
differ in the ethnic group involved, a factor that may play a role in the fiber  11 
type  distribution.  Also  Zhang  et  al.,  (2003),  in  the  methods  section  do  not  12 
specify the kind of training the subjects were involved in (‗any specific training‘  13 
is an unclear term that does not provide information about the physical activity  14 
levels that may play a drastic role in the architecture of the muscle fibers). The  15 
results of our study for the proportion of muscle fibres in  pre-training biopsy  16 
sample were for II allele carriers: Type I 50.2 ± 1.5 % pre, Type IIA 28 ± 1.1 % and  17 
Type IIB 21.9 ± 1.1 %, whereas for the homozygotes for the D allele, Type I fibres  18 
were 50.8 ± 3 %, Type IIA 26.2 ± 1.8 % and Type IIB 22.9 ± 2.3 % (mean ± SEM,  19 
table  3.2,  results  section).  Our  results  demonstrate  that  there  is  either  no  20 
influence of ACE genotype on fiber type composition, or the effect is too small  21 
to  influence  the  muscle  function  in  our  cohort.  Since  almost  20-80  %  of  the  22 
phenotypic  variation  seems  to  be  attributed  to  inherited  factors,  there  is  a  23 
possibility  that  numerous  unidentified  genes  to  date  collectively  influence  24 
muscle function (Williams and Folland, 2008).  25 
Type II fibres (IIA and IIB) have bigger motor neuron size and higher recruitment  26 
frequency as well as contraction speed, facts that lead to the prospect that such  27 
fibres may yield greater forces per units of cross-sectional area. Indeed, Stienen  28 
and his collaborators (1996) proved that type IIA and IIB fibres are capable of  29 
producing greater forces as compared with the corresponding values of type I. In  30 
the present study, significant differences were found pre and post in average  31 
cross-sectional area of type IIA fibres for individuals with DD genotype, and also  32 
in pre and post measurements for II individuals type I fibres (see Table 3.2 in the  33 
results  section).  Despite  the  genotype  specific  differences,  there  was  no  34 
interaction between genotype and changes in AVECSA (see results section, table  35   62 
3.2). Those findings come in line with all the previously discussed papers and  1 
support the evidence that muscle hypertrophy has occurred. Despite that, it is  2 
still  not  clear  why  or  if  the  ACE  genotype  is  related  to  muscle  fiber  type  3 
distribution and size, or whether or not the ACE I/D polymorphism may be in  4 
linkage disequilibrium with another functional variant in an adjacent gene which  5 
is  in  fact  responsible  for  the  muscle  fiber  type  distribution.  In  this  study,  6 
circulating ACE activity and ACE genotype were assessed in order to detect any  7 
effect on the type or the cross sectional area of skeletal muscle fibers. Since  8 
local RAS exists (review by Jones and Woods, 2003), local ACE activity (and ANGII  9 
production)  in  skeletal  muscle  may  be  a  factor  that  would  influence  muscle  10 
properties (Williams et al., 2005).  11 
Neural adaptation to exercise is a largely disputed issue that yet remains to be  12 
elucidated. Adaptations occurring the first five weeks are mainly neural (Sale,  13 
1988), with the subjects‘ improvements in strength resulting from the learning  14 
effect, which in turn is familiarization with the apparatus and exercise. It is very  15 
important to determine the duration of the neurogenic effect so as to exclude  16 
all the phenomenal strength gains and concentrate in the substantial effects.  17 
Moritani and DeVries (1979) pointed out that significant gains in muscle strength  18 
have  been  shown  following  short  periods  of  resistance  training,  which  are  19 
generally  regarded  as  being  too  short  to  elicit  morphological  changes  in  the  20 
muscle.  Hence,  it  would  seem  that  the  noted  increase  in  strength  is  mainly  21 
because of an ability to activate the muscle in a more efficient way. In his study,  22 
hypertrophy became the dominant factor after the first 3 to 5 weeks (Moritani  23 
and  DeVries,  1979).  Another  study  (Narici  et  al.,  1989)  concluded  that  the  24 
increase  observed  in  cross-sectional  areas  of  the  muscles  of  the  human  25 
quadriceps is responsible only for the 40% of the increase in total force, while  26 
the  remaining  60%  is  attributed  to  a  possibly  increased  neural  drive  plus  27 
architectural changes occurring within the muscle.  If  we sum up the existing  28 
literature references, 5 weeks seem to be the golden mean, with a range in  29 
values from 2 to 8 weeks. In the present study, 12 weeks were chosen in order to  30 
eliminate as much as possible the changes ascribed to the ‗learning effect‘. In  31 
figure 3.7 for example, we can see that on week 2 of the trained leg, there is a  32 
highly  significant  increase  of  isometric  force  mainly  (751  ±  30.8  for  week  2,  33 
821.6 ± 38.8 for week 3, 9.4 % increase in only one week) and also in figure 3.8  34 
(448.9  ±  20.5  for  week  2,  480.6  ±  17.4  for  week  3.7  %  increase  in  only  one  35   63 
week), all those changes mainly attributed to increased neural drive. Force also  1 
seems to plateau in all isometric and isokinetic angles and velocities between  2 
weeks 3 and 8; after 8
th week we can define the actual gains of the training  3 
program in the trained leg. The intensity and the volume of the training were set  4 
to  elicit  both  strength  gains  and  muscle  hypertrophy  (Baechle  1994).  As  5 
mentioned  previously,  a  measure  of  hypertrophy  is  specific changes  in  cross- 6 
sectional areas of the skeletal muscle fibres.  Therefore, since in the present  7 
study  strength  training  was  applied,  it  would  be  expected  that  muscle  fiber  8 
types  with  plasticity  towards  resistance  training  are  to  present  the  most  9 
changes. Indeed, as it is presented in table 3.2 in the results section, there was  10 
a significant increase in cross-sectional area of both type IIA and type IIB fibres,  11 
for all subjects (II+DD) and for DD genotype, a significant increase in  type IIA  12 
fibre cross-sectional area.   13 
In  a  training  study  (Folland  et  al.,  2000),  involving  isometric  and  isokinetic  14 
(dynamic) knee extension (one in each leg) among subjects categorized in II, ID  15 
and DD group, it was found that the ID genotype (Folland et al., 2000), showed  16 
the greatest strength improvement, followed by the group with the DD genotype  17 
and then the II genotype group. It was also found that the response to training  18 
was  highly  genotype  dependent,  favoring  the  individuals  with  the  presence  19 
rather than the absence of the D allele. Moreover, it was found that the ID and D  20 
subject improved their quadriceps strength 97 % and 66 % more than II subjects  21 
(Folland et al., 2000). In the present study, only subjects who carried the two  22 
alleles of the gene were qualified to participate (see methods section). It was  23 
therefore hypothesized that using the two extremes (II and DD) would result in  24 
more obvious and significant differences in all the parameters tested. Overall,  25 
for the trained leg, the gains in isometric strength were similar between the two  26 
groups (26.14 % for the II allele carriers and 23.5 % for DD allele carriers), and  27 
moreover  II  allele  carriers  gained  more  (although  non-significant)  strength,  28 
contradicting Folland et al., (2000).  29 
As  it  has  been  mentioned  before,  a  larger  and  a  more  equally  distributed  30 
between the genotypes sample size is essential for yielding meaningful results.  31 
As the recent update on ACE (Thompson et al., 2006) and the human gene map  32 
for physical performance and health-related fitness phenotypes (  Bray et al.,  33 
2009)  indicate,  ‗The  ACE  gene  continues  to  be  by  far  the  most  extensively  34   64 
studied  of  any  gene,  with  at  least  58  articles  examining  the  effect  of  an  1 
insertion/deletion  polymorphism  on  fitness  and  performance  traits.  The  2 
conflicting  findings  among  the  many  studies  for  the  ACE  gene  exemplify  the  3 
complexity of genetic studies of complex traits. Indeed despite the enormous  4 
amount of attention that the ACE gene has received, it is still not possible to  5 
conclude  with  certainty  whether  the  common  polymorphism  in  ACE  is  truly  6 
involved in human variation in fitness and performance phenotypes and their  7 
response to regular exercise. This is primarily, but not exclusively, due to the  8 
fact that studies are almost universally underpowered and because an unknown  9 
number of negative studies remain unpublished‘ (Thompson et al., 2006; Bray et  10 
al., 2009).  11 
Knowledge of physiological mechanisms regulating muscle growth would help in  12 
the  design  of  exercise,  nutritional  or  pharmacological  interventions  aimed  at  13 
improving the effect of strength training and restoring muscle strength and size  14 
after prolonged inactivity. In addition to this, the identification of a potential  15 
‗good‘ or ‗bad‘ responder will assist in the construction of a more specialized  16 
training schedule.   17 
  18 
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  1 
Limitations of the current study  2 
There  are  several  limitations  that  need  to  be  acknowledged  and  addressed  3 
regarding  the  present  study.  The  first  limitation  concerns  the  extensively  4 
discussed sample size. As it was mentioned on the methods and results section,  5 
the power of this study, indicated by both a priori power analysis as well as  6 
observed power acquired during the conduction of statistical tests, is very low.  7 
Two-tailed analysis was preferred due to the fact that the direction of the effect  8 
was unknown, as controversial studies exist. If we had chosen to use a one-tailed  9 
analysis , the subjects needed to complete the study would be less, but still  10 
almost twice the sample size we used (37 subjects to detect a significant  one- 11 
tailed correlation of magnitude r = 0.30 with a power of 0.80 with the level of  12 
alpha set at 0.05). However, the study was time constrained by the due date of  13 
the course, so the desired number of subjects was difficult to achieve.  14 
  15 
The second limitation has to do with the self-reported physical activity levels  16 
which play a critical role in the findings of the study, as they confound the main  17 
significant result of the study. Physical activity (hours per week) was assessed  18 
via questionnaires, with some of the subjects reporting even 15 hours of physical  19 
activity per week. The type of activity was not specified at all occasions, with  20 
some of the subjects stating walking and cycling as their main activity, while  21 
others reported taking part in recreational rugby and soccer activities. Since the  22 
force  generation  is  profoundly  affected  by  the  activity  undertaken  and  may  23 
mediate the effect of the genotype (in the present study), care should be taken  24 
in controlling the levels of physical activity. Structured recreational exercise,  25 
such  as  the  activities  aforementioned  might  be  very  important  as  they  all  26 
provide  muscle  loading  and  training.  Furthermore,  these  levels  are  quite  27 
substantial when compared to a sedentary background.  28 
Another  limitation  I  encountered  was  the  absence  of  post-training  29 
anthropometric  measurements.  Alterations  in  the  weight  of  the  participants  30 
(weight gain or weight loss) in addition with reduced physical activity towards  31 
the  end  of  the  study  may  possibly  have  a  severe  impact  on  the  variables  of  32 
interest,  for  example  in  the  force  output  or  the  skeletal  muscle  fiber  33   66 
composition or cross-sectional area. Furthermore, fat free mass would be a more  1 
accurate parameter for the description of the population and consequently for  2 
any differences between the two groups of individuals (for example DD group  3 
may have presented lower fat free mass in the beginning of the study compared  4 
to the II group but after the training intervention, the opposite might have been  5 
observed), as well as a more useful tool for explaining the observations made.  6 
  7 
  8 
Conclusion  9 
  10 
The present study showed that twelve weeks of strength training on the trained  11 
leg of 18 subjects caused greater isometric strength gains in homozygotes for the  12 
ACE DD allele compared to homozygotes for the II allele, although participants  13 
had  no  baseline  differences  depending  on  genotype.  Muscular  hypertrophy  14 
occurred  as  a  result  of  training,  but  no  differences  were  observed  between  15 
groups concerning neither the muscle fiber type distribution nor the muscle fiber  16 
cross-sectional  area.  Circulating  ACE  activity  was  unaffected  by  the  17 
intervention,  and  was  not  associated  with genotype.  Baseline  circulating  ACE  18 
activity correlated strongly and positively with baseline isometric and isokinetic  19 
strength,  an  indication  of  a  potential  role  of  ANGII  as  a  growth  factor.  The  20 
limitations of the current study, reduced power in particular, indicate that a  21 
larger cohort is essential to confirm our results. Also, local ACE activity (and  22 
ANGII production) in skeletal muscle should be assessed, as they may possibly  23 
affect muscle properties. Therefore, our findings suggest a possible role for ACE  24 
gene  polymorphism  in  the  regulation  of  human  skeletal  muscle  strength,  but  25 
limited  statistical  power  and  confounding  factors  prevented  us  from  drawing  26 
clear conclusions.   27 
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  1 
Appendix  Table  1:  Correlations  between  baseline  and  post-training  2 
characteristics in all angles and Circulating ACE activity, pre- and post-training.  3 
                                
 
Circulating ACE activity pre-
training     Circulating ACE activity post training 
DISOM5pre  r= 0,46        DISOM5post  r= 0.29         
   p= 0.05*           p= 0.24         
                       
DISOM30pre  r= 0,25      DISOM30post  r= 0.33         
   p= 0.31           p= 0.18         
                       
DISOM60Pre  r= 0,06      DISOM60post  r= -0.08         
   p= 0.98           p= 0.77         
                       
DISOK60pre  r= - 0,11      DISOK60post  r= 0.30         
   p= 0.65           P= 0.22         
                       
DISOK180pre  r= 0,51      DISOK180post  r= 0.36         
   p= 0.03*           p= 0.13         
                       
NDISOM5pre  r= 0.38      NDISOM5post  r= 0.26         
   p= 0.11           P= 0.28         
                       
NDISOM30pre  r= 0.03      NDISOM30post  r= 0.27         
   p= 0.90           p= 0.26         
                       
NDISOM60pre  r= -0.04      NDISOM60post  r= 0.32         
   p= 0.88           p= 0.19         
                       
NDISOK60pre  r= 0,09      NDISOK60post  r= 0.34         
   p= 0.69           p= 0.17         
                       
NDISOK180pre  r= 0.14      NDISOK180post    r=-0,006         
   p= 0.57              p= 0.99             
                                
D=untrained leg, ND=trained leg, ISOM:isometric training, ISOK:isokinetic  4 
training, r= Pearson‘s correlation coefficient *P <0.05  5 
  6 
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Appendix  Table  2.  :  Correlations  between  baseline  characteristics  (baseline  1 
circulating  ACE  activity,  Isometric  /  Isokinetic  force  and  muscle  fibers  2 
architecture)  and  anthropometric  characteristics  as  well  as  physical  activity  3 
levels.  4 
  
Weight 
(kg) 
Height 
(m) 
BMI 
(kg/m2) 
Physical Activity 
Levels (h/week) 
           
ACE ACT Pre  r= 0.62  r= 0.65  r= 0.27  r= 0.16 
  p= 0.01 *  p= 0.01 *  p= 0.27  p= 0.52 
           
DISOM5pre  r= 0.19  r= 0.38  r= -0.15  r= 0.27 
  p= 0.43  p= 0.12  p= 0.55  p= 0.28 
           
DISOM30pre  r= 0.22  r= 0.32  r= -0.02  r= 0.15 
  p= 0.37  p= 0.19  p=0.90  p= 0.55 
           
DISOM60Pre  r= 0.02  r= 0.10  r= -0.10  r= -0.05 
  p=0.92  p= 0.66  p= 0.69  p= 0.84 
           
DISOK60pre  r= -0.12  r= 0.01  r= -0.04  r= 0.04 
  p= 0.962  p= 0.98  p= 0.87  p= 0.87 
           
DISOK180pre  r= 0.31  r= 0.43  r= 0.01  r= 0.26 
  p=0.20  p= 0.07  p= 0.95  p= 0.29 
           
NDISOM5pre  r= 0.33  r= 0.58  r=-0.18  r= 0.39 
  p= 0.18  p= 0.01 *  p= 0.47  p= 0.10 
           
NDISOM30pre  r= 0.2  r= 0.40  r= -0.19  r= 0.49 
  p= 0.42  p=0.09  p= 0.44  p= 0.03 * 
           
NDISOM60pre  r= -0.05  r= 0.21  r= -0.38  r= 0.31 
  p= 0.84  p= 0.39  p=0.11  p= 0.20 
           
NDISOK60pre  r= 0.22  r= 0.30  r= 0.01  r= 0.15 
  p= 0.37  p= 0.22  p= 0.99  p= 0.53 
           
NDISOK180pre  r= 0.11  r= 0.27  r= -0.15  r= 0.44 
  p= 0.64  p= 0.28  p= 0.55  p= 0.06 
           
TypeIPreCent  r= 0.19  r= 0.27  r= -0.01  r= 0.13 
  p= 0.44  p= 0.27  p= 0.99  p= 0.60 
           
TypeIIaPreCent  r= -0.23  r= -0.43  r= 0.15  r= -0.29 
  p= 0.35  p= 0.07  p= 0.53  p= 0.23 
           
TypeIIbPreCent  r= -0.34  r= 0.01  r= -0.10  r= 0.05 
  p= 0.89  p= 0.95  p= 0.68  p= 0.84 
           
AVECSAIPre  r= 0.13  r= -0.04  r= 0.32  r= -0.26 
  p= 0.58  p= 0.84  p= 0.19  p= 0.28   70 
           
AVECSAIIaPre  r= 0.005  r= -0.25  r=0.34  r= -0.35 
  p= 0.98  p= 0.31  p= 0.16  p= 0.15 
           
AVECSAIIbPre  r= 0.14  r= -0.4  r= 0.32  r= -0.19 
  p= 0.57  p= 0.87  p= 0.19  p= 0.45 
           
                 
D= untrained leg, ND=trained leg, ISOM: Isometric training, ISOK: Isokinetic  1 
training, r= Pearson‘s correlation coefficient *P <0.05  2 
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1. Describe the basic purposes of the research proposed.   7 
Ageing is accompanied by loss of muscle strength and size that can impair  8 
mobility (Hyatt, et al., 1990). Similar effects on muscle strength and size are  9 
also seen during prolonged inactivity (MacDougall, et al., 1980) resulting from  10 
bed rest, space flight or limb immobilization. Strength training can restore  11 
muscle strength and size after periods of prolonged inactivity, although the most  12 
effective strength training program remains to be elucidated (Jones, 1992).  13 
Knowledge of physiological mechanisms regulating muscle growth would help in  14 
the design of exercise, nutritional or pharmacological interventions aimed at  15 
improving the effect of strength training and restoring muscle strength and size  16 
after prolonged inactivity.  17 
  18 
Angiotensin converting enzyme (ACE) is a key component of the circulating  19 
human renin-angiotensin system generating angiotensin II (AII), a  20 
vasoconstrictor, and degrading vasodilator kinins (Dzau, 1988). Local ACE  21 
expression may also modulate tissue growth processes as both AII and kinins  22 
appear to have growth regulatory effects (Geisterfer, et al., 1988; Ishigai, et al.,  23 
1997). A recent study has shown the importance of ACE in the regulation of  24 
skeletal muscle growth, using an experimental model of compensatory  25 
hypertrophy in rats (Gordon, et al., 2001). However, no similar study has yet  26 
directly evaluated the role of ACE in the regulation of skeletal muscle growth in  27 
humans.  28 
  29 
30   89 
  1 
A functional polymorphism of the ACE gene has been identified, with the  2 
absence (deletion allele, D) rather than the presence (insertion allele, I) of a 287  3 
base-pair fragment associated with higher tissue (Danser, et al., 1995) and  4 
serum (Rigat, et al., 1990) ACE activity. Each human has 2 alleles, and  5 
consequently can be II, ID or DD. One study used genotype as an indirect marker  6 
of ACE activity, and compared the responses to strength training (Folland, et al.,  7 
2000). This study found that individuals with at least one D allele had greater  8 
gains in strength after a strength training programme than those without a D  9 
allele. This finding is consistent with the key role of ACE in the regulation of  10 
skeletal muscle hypertrophy in rats (Gordon, et al., 2001). However, further  11 
research is required in humans to correlate ACE activity directly with the  12 
training response (rather than using the genetic marker alone), and also to  13 
measure skeletal muscle growth directly (rather than measuring muscle strength  14 
alone).  15 
  16 
Skeletal muscle fibres develop by fusion of myoblasts that are stimulated to  17 
proliferate by growth factors. Myoblast fusion is generally coupled with the  18 
onset of differentiation and at this point they lose the ability to divide. In adult  19 
cells, however, some myoblasts persist in a quiescent state (as satellite cells)  20 
that can be reactivated to proliferate and fuse to replace other damaged muscle  21 
cells or promote muscle growth. A reduction in the proliferative potential for  22 
satellite cells will limit the muscle's ability to repair damage or hypertrophy in  23 
response to increased physical activity levels. The mechanism regulating cell  24 
senescence are unclear but will be intimately related to cell cycle regulation.  25 
  26 
Periodic synthesis and destruction of regulatory sub-units, known as a cyclins,  27 
result in sequential activation and inactivation of cyclin-dependent kinases  28 
(cdks) which provide the primary means of cell cycle regulation (Arellano &  29 
Moreno, 1997). At least 16 mammalian cyclins have been identified and all  30 
contain a homologous domain (the cyclin box) used to bind and activate cdks. In  31 
addition to cyclin binding, other levels of regulation also exist for controlling cdk  32 
activity during the cell cycle. Phosphorylation regulates kinase activity (Pagano,  33 
1997) and ubiquitin-mediated proteolysis can target cyclins and other regulators  34   90 
(LaBaer, et al., 1997). Association with two proteins families, the cdk inhibitors,  1 
is also an important regulator where some inhibitors appear to regulate the cell  2 
cycle positively by functioning as an assembly factor for cyclin/cdk complexes  3 
(Deng, et al., 1995).  4 
  5 
The two cyclin-dependent kinase inhibitor families are known as the Cip/Kip  6 
family and the INK4 family. The INK4 family consists of p15, p16, p18 and p19  7 
and these proteins specifically interact with cdk4 and cdk6 (Carnero & Hannon,  8 
1998). The Cip/Kip family, however, can act on most cyclin/cdk complexes and  9 
even on some kinases unrelated to cdks. The first member of this family to be  10 
isolated was p21 and the other two members are p27 and p57. Although reported  11 
mutations in the p21 gene are rare, the most commonly reported mutation is in  12 
codon 31 where a base change from AGC to AGA causes an amino acid  13 
substitution from serine to arginine and accelerates proliferation (Polyak, et al.,  14 
1994).  15 
  16 
The primary aim of this study, therefore, will be to investigate the influence of  17 
ACE activity on the extent of muscle growth and strength development achieved  18 
during strength training. The influence of ACE genotype will also be  19 
investigated. A secondary aim of this study will be to establish the influence of  20 
p21 expression on muscle growth and strength development and its relation to  21 
the p21 genotype.  22 
2. Outline the design and methodology of the project.  Please include in this  23 
section details of the proposed sample size.  24 
We propose to study fifty normal healthy male subjects aged between 18 and 35  25 
years (this sample size is in line with the statistical procedures to be used). All  26 
subjects will be in good health at the time of testing. Only volunteers with no  27 
history of musculoskeletal injury who are physically active but had not engaged  28 
in any structured strength-training programme of the quadriceps muscle group  29 
during the 6 months preceding the initiation of the study will be eligible to  30 
participate. Subject eligibility will be assessed by completion of a medical and a  31   91 
physical activity questionnaire. Subjects will also be required to read and sign  1 
the enclosed information sheet.  2 
  3 
The quadriceps muscle group of both legs will be trained using a 12-week  4 
strength training programme. A range of functional, biochemical and histological  5 
measurements will be conducted, both before and after the training programme,  6 
and DNA samples (ACE genotype) will be extracted from venous blood (or saliva)  7 
before the training programme. The genetic material collected will not be used  8 
for any other purpose than that specified. All testing will be conducted during  9 
two 2-week periods prior to and after the training programme. The total  10 
duration of the project will be 16 weeks. All testing and training will take place  11 
in the Exercise and Nutrition laboratory at Glasgow Royal Infirmary and the  12 
Exercise Physiology laboratory in the West Medical Building.   13 
  14 
Protocols  15 
Measurements will include muscle strength, blood analysis, and analysis of  16 
muscle samples obtained by biopsy.  17 
  18 
Muscle strength: Prior to initial strength testing, each subject will be  19 
familiarised with the testing protocols during a full practice session. A standard  20 
test of isometric knee extension strength at joint angles of 30º, 60º and 90º will  21 
be carried out. The highest force production of at least 3 attempts at each joint  22 
angle (a few more attempts are sometimes required to produce a plateau in  23 
force production) will be recorded before and after training. Isokinetic  24 
dynamometry (Kin-Com) will be used to determine the maximal torque that can  25 
be produced during leg extension at an angular velocity of 60º per sec before  26 
and after training. The highest torque of at least 3 attempts (a few more  27 
attempts are sometimes required to produce a plateau in torque production) will  28 
be recorded before and after training. The maximum load that can be lifted  29 
once (1-RM) on a leg extension machine so that the lower part of the leg is  30 
parallel with the floor will be recorded before and after training, and weekly  31 
during the training programme. Each subject will complete successive  32   92 
repetitions, separated by 30-sec rest periods, with progressively increasing loads  1 
until the 1-RM is determined. Both legs will be tested   2 
  3 
Blood analysis: Before and after the 12 week intervention period, a resting blood  4 
sample (20-mL) will be obtained from a superficial forearm vein for analysis of  5 
plasma ACE activity and ACE/p21 genotypes (before training only). Plasma will  6 
be separated immediately from 10-mL of whole blood by centrifugation at 1500  7 
g for 10 minutes and stored at -80C until analysis. ACE and p21 genotype will be  8 
determined by a polymerase chain reaction (PCR; O'Dell, et al., 1995; Tsai, et  9 
al., 2002). ACE activity will be assayed using a spectrophotometric technique  10 
(Sigma Diagnostics, Poole, UK) based on the method developed by Holmquist, et  11 
al., (1979). The investigators will remain blind to the subject's genotype.  12 
  13 
Muscle analysis: These will be obtained from the vastus lateralis by the  14 
Bergstrom needle biopsy technique (Bergstrom, 1975) as previously approved by  15 
the university ethics committee. Portions of the muscle samples will be analysed  16 
using light microscopy and computer-based planimetry for the cross-sectional  17 
area of each major fibre type. In addition, portions of the muscle samples will  18 
be analysed using the traditional ATPase histochemistry technique for  19 
delineation of the fibre types (coefficient of variation of approximately 10 %  20 
(Coggan, 1995)) while other portions will be prepared for analysis of MHC  21 
composition (Salviati, et al., 1984). Relatively small shifts in fibre type can now  22 
be detected successfully using the more recently developed analysis of MHC  23 
isoforms (Pette, et al., 1999). ACE and p21 gene expression will be analysed in  24 
portions of the muscle samples. ACE mRNA transcripts will be quantified using  25 
reverse transcription-PCR (Studer, et al., 1994). p21 mRNA will be measured by  26 
PCR-based restriction analysis.   27 
  28 
Training: Strength training of the quadriceps muscle group will take place using  29 
a leg extension device, 3 times per week for 12 weeks. Each training session will  30 
consist of 1 "warm-up" set of 10 repetitions at 75 % of the training load, and 4  31 
sets of 10 repetitions at 100 % of the training load. Rest periods of 1 minute will  32   93 
separate exercise sets. The training load is defined as that load which can be  1 
used with successful completion of 10 repetitions and no more (10-RM load) -  2 
estimated at 70 % 1-RM. Each subject's 1-RM will be re-assessed weekly, and the  3 
training load adjusted as necessary to maintain a constant training stimulus.  4 
Each repetition of the exercise will consist of a concentric and eccentric  5 
contraction. All training sessions will be conducted in the specified laboratories  6 
and will be directly supervised.  7 
  8 
  9 
  10 
Data analysis: MANOVA will be used to examine the variables at baseline and the  11 
responses to training within and between the genotypes observed. In addition,  12 
Pearson correlations will be conducted to examine the relationships between  13 
plasma ACE activity and the magnitude of the other variables at baseline and the  14 
change in magnitude over the training programme.  15 
3. Describe the research procedures as they affect the research subject and any  16 
other parties involved.  17 
  18 
All tests will take place in the Exercise and Nutrition laboratory at Glasgow Royal  19 
Infirmary and the Exercise Physiology laboratory in the West Medical Building.  20 
They will be conducted according to the “Code of Practice for Conducting  21 
Experiments in Non-Patient Human Volunteers (including Handling and  22 
Disposal of Human Blood, Urine and Sputum)”, approved by the University  23 
Ethics Committee on October 16, 2000. Dr Yannis Pitsiladis or a qualified (CPR- 24 
trained) and experienced colleague will be present at all tests. Dr Pitsiladis is a  25 
certified phlebotomist and trained in CPR and Advanced Life Support. All  26 
investigators are trained in CPR. Defibrillator and emergency drugs are on site in  27 
the laboratory.  28 
  29 
Genetic material will also be disposed of using the same methods as for the  30 
disposal of blood i.e., “Code of Practice for Conducting Experiments in Non- 31   94 
Patient Human Volunteers (including Handling and Disposal of Human Blood,  1 
Urine and Sputum)”.  2 
  3 
Some subjects may experience mild discomfort during the sampling of blood  4 
from a forearm vein. Upon withdrawal of the needle, firm pressure is maintained  5 
over the site for at least 5 minutes to prevent bruising. Importantly, if a blood  6 
sample cannot be obtained readily or if the subject finds the experience too  7 
uncomfortable then the experiment will be halted. No more than 20-mL of blood  8 
will be taken from any subject.  9 
  10 
Obtaining muscle biopsies from the lateral head of the quadriceps muscle is a  11 
standard and relatively common practice in studies of muscle metabolism in  12 
exercise. It is not uncommon for multiple sites to be biopsied, without incident, in  13 
a single experiment. However, we wish to sample from a single site only. Professor  14 
Wilhelmina Behan, Dr Stephen Turner, Dr Jonathan Fuld or Dr Margaret McEntagert  15 
who are all experienced in this procedure will take the biopsies. This procedure  16 
has a small risk of inducing pain, haematoma, haemorrhage or infection; these  17 
effects are confined to the sample site if they occur. This risk will be minimized  18 
by using (a) experienced medical personnel, (b) a fine gauge biopsy needle and (c)  19 
local anaesthesia.  20 
  21 
Potential participants will be identified either by personal contact or by  22 
advertisement. They will be asked to meet with the investigators to discuss the  23 
project and whether they would be suitable as a subject. All subjects will be  24 
healthy individuals without a history of any significant medical problem(s). The  25 
good health of each subject will be established prior to the study by taking the  26 
subject's medical history, which is supported by a written assurance from the  27 
subject. Subjects with a history of cardiorespiratory, musculoskeletal or  28 
neurological disease/injury will be excluded from participation, as will those  29 
having an acute upper respiratory tract infection. Subjects who take drugs  30 
(recreational or performance enhancing drugs) or who have consumed alcohol  31 
within 48-hrs of an experiment will be also excluded.  32   95 
  1 
Close supervision of the subject will be ensured at all times by the supervising  2 
investigator. If a problem is indicated, the investigator will ask further questions  3 
to establish whether there is a technical problem that could lead to potential  4 
hazard or whether the subject is feeling unwell. In either case, the test will be  5 
immediately halted. All subjects will be routinely instructed to cease exercising  6 
if they experience any discomfort or have any concern for their well being.   7 
  8 
The risks associated with performing maximal exercise are minimal as long as  9 
the subject is appropriately instructed and familiarised with the device prior to  10 
participation in addition to being appropriately supervised during the  11 
experiment. All exercise bouts are preceded by a 5 min "warm-up" and followed  12 
by a 5 min "warm-down".   13 
4. What in your opinion are the ethical considerations involved in this  14 
proposal?  (You may wish for example to comment on issues to do with  15 
consent, confidentiality, risk to subjects, etc.)  16 
  17 
Exercise has negligible risk to healthy adults, although maximal exercise has a  18 
small risk of inducing myocardial ischaemia.  19 
  20 
The subjects will complete a medical questionnaire and provide their written  21 
consent with the option to withdraw from training or testing at any point.  22 
  23 
The insertion of a catheter into a vein may rarely cause irritation at the site of  24 
insertion, venospasm (or constriction of the cannulated vein which may lead to  25 
interference with blood flow through it) and phlebitis. These risks are minimized  26 
in this investigation by the short duration of the test and by the procedures  27 
described above.  28 
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The  taking  of  muscle  biopsies  has  a  low  risk  of  inducing  pain,  haematoma,  1 
haemorrhage or infection confined to the sample site. This risk can be minimized  2 
with the use of experienced medical personnel, a fine gauge biopsy needle and  3 
local anaesthesia.  4 
  5 
Blood and sputum will be handled, stored and disposed of according to standard  6 
health and safety procedures.  7 
5. Outline the reasons which lead you to be satisfied that the possible benefits  8 
to be gained from the project justify any risks or discomforts involved.  9 
  10 
This research will establish the influence of ACE/p21 genotype, p21 expression  11 
and ACE activity on muscle growth and strength development from a training  12 
programme. Understanding the physiological mechanisms regulating muscle  13 
growth and strength development will inform the design of exercise, nutritional  14 
or pharmacological interventions to improve rehabilitation after prolonged  15 
inactivity. The low risk and slight discomfort associated with the procedures are  16 
worthwhile in relation to the data being generated.  17 
  18 
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  1 
  2 
6. Who are the investigators (including assistants) who will conduct the research  3 
and what are their qualifications and experience?  4 
  5 
Dr Yannis Pitsiladis PhD MMedSci BA, Mrs Heather Collin (Technician), Mr Stewart  6 
King (MSc student) and a number of L4 Physiology and Sports Science students.  7 
The principal investigators have wide ranging experience of exercise testing over  8 
periods of up to 10 years without incident.   9 
  10 
Professor Wilhelmina M Behan MD FRCPath, Dr Margaret McEntagert MRCP BSc,  11 
Dr Stephen Turner  (MBChB, MRCS) and Dr Jonathan Fuld MRCP have extensive  12 
experience with the muscle biopsy technique without incident.  13 
  14 
7. Are arrangements for the provision of clinical facilities to handle emergencies  15 
necessary?  If so, briefly describe the arrangements made.  16 
  17 
In the event of an emergency, guidelines previously approved by the ethics  18 
committee will be followed.  19 
  20 
In the event of an untoward incident that is not an emergency, the supervising  21 
Principal Investigator will administer appropriate first aid, if necessary. The  22 
subject will not be permitted to leave the laboratory until he has fully  23 
recovered. The subject will be encouraged to contact his local GP. The subject  24 
will be told that one of the Principal Investigators will conduct a follow-up by  25 
telephone at the end of the same day. The subject will also be provided with 24- 26 
hour contact numbers for both Principal Investigators.  27 
  28 
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8. In cases where subjects are identified from information held by another party  1 
(for example, a doctor or hospital) describe the arrangements whereby you gain  2 
access to this information.  3 
  4 
 N/A  5 
  6 
  7 
9. Specify whether subjects will include students or others in a dependent  8 
relationship.  9 
  10 
Some students may be recruited but will be under no pressure from staff to  11 
participate in the study.  12 
  13 
  14 
  15 
10. Specify whether the research will include children or those with mental  16 
illness, disability or handicap.  If so, please explain the necessity of using these  17 
subjects.  18 
  19 
 No.  20 
  21 
  22 
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  1 
  2 
11. Will payment be made to any research subject?  If so, please state the level  3 
of payment to be made, and the source of the funds to be used to make the  4 
payment.  5 
  6 
Transportation costs to the laboratory will be provided.  7 
  8 
  9 
12. Describe the procedures to be used in obtaining a valid consent from the  10 
subject.  Please supply a copy of the information sheet provided to the  11 
individual subject.  12 
  13 
Each subject will be provided with a consent form outlining both the testing and  14 
training procedures, which asks them for their written consent to participate in  15 
the project with the option to withdraw at any time (see enclosed copy). A  16 
verbal explanation will also be given and any queries answered. A health  17 
questionnaire will also be given. If there is some doubt of the subject's eligibility  18 
for the study, the subject will be excluded.  19 
  20 
  21 
13. Comment on any cultural, social or gender-based characteristics of the  22 
subject which have affected the design of the project or which may affect its  23 
conduct.  24 
  25 
All subjects are male. This constraint is imposed for standardisation purposes.  26 
  27 
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14. Give details of the measures which will be adopted to maintain the  1 
confidentiality of the research subject.  2 
  3 
The information obtained will be anonymised and individual information will not  4 
be passed on to anyone outside the study group. The results of the tests will not  5 
be used for selection purposes.  6 
  7 
  8 
15. Will the information gained be anonymized?  If not, please justify.  9 
  10 
Yes  11 
  12 
  13 
16. Will the intended group of research subjects, to your knowledge, be involved  14 
in other research?  If so, please justify.  15 
  16 
 No.  17 
  18 
  19 
17. Date on which the project will begin (10
th November, 2002) and end (30
th  20 
August, 2006)  21 
  22 
  23 
18.  Please state location(s) where the project will be carried out.  24 
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Exercise Physiology laboratories, West Medical Building and Exercise.  1 
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INFORMATION SHEET  1 
  2 
Institute of Biomedical and Life Sciences  3 
University of Glasgow  4 
  5 
INFORMATION SHEET  6 
  7 
Genetic factors influencing the response of skeletal muscle to strength  8 
training  9 
  10 
You are invited to take part in a research study. Before you decide it is  11 
important for you to understand why the research is being done and what it will  12 
involve. Please take time to read the following information carefully and discuss  13 
it with friends, relatives and your GP if you wish. Ask us if there is anything that  14 
is not clear or if you would like more information. Take time to decide whether  15 
or not you wish to take part.  16 
  17 
Thank you for reading this.  18 
  19 
What is the purpose of the study? We wish to investigate how muscle growth is  20 
achieved by strength training. In particular, how an enzyme called angiotensin  21 
converting enzyme (ACE) and a protein called p21 may influence muscle growth.  22 
Your participation in this study may provide you with information that relates to  23 
how your muscles adapt to strength training.  24 
  25 
Why have I been chosen? You have been selected as a possible participant in  26 
this investigation because you are physically active (but not resistance-trained)  27 
and in good health. Fifty volunteers are being sought.  28 
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Do I have to take part? It is up to you to decide whether or not to take part. If  1 
you decide to take part you will be given this information sheet to keep and be  2 
asked to sign a consent form. If you decide to take part you are still free to  3 
withdraw at any time and without giving a reason.  4 
  5 
What will happen to me if I take part? Initially you will be asked to visit the  6 
laboratory on at least three occasions over a two week period to conduct the  7 
initial  assessments  (i.e.  baseline  tests)  (see  Table).  Each  visit  will  last  8 
approximately 1 hour. On the first occasion, you will be asked to complete two  9 
confidential questionnaires; the first will allow us to obtain information related  10 
to  your  general  health;  and  the  second  will  allow  us  to  quantify  your  past  11 
exercise/activity  involvement.  Following  this,  a  small  muscle  sample  will  be  12 
obtained  from  your  non-dominant  thigh.  This will require  a fine needle to be  13 
inserted into your thigh muscle, while you are lying down at rest (sample size  14 
approximately  100  milligrams  of  muscle).  To  minimize  any  discomfort,  a  local  15 
anesthetic will be injected into the sample site prior to the sample being taken.  16 
Once  recovered  (approximately  30  min),  you  will  be  familiarized  with  the  17 
strength  test,  related  equipment  and  procedures.  The  strength  test  involves  18 
assessing thigh strength at fixed joint angles of 30º, 60º and 90º. In other words,  19 
static force (i.e. no movement of the leg) will be measured with the knee bent  20 
at  the  angles  stated  above.  The  highest  force  production  (RM)  of  at  least  3  21 
attempts  at  each  joint  angle  will  be  recorded.  Each  leg  will  be  tested  22 
separately. The strength test will be repeated on two subsequent occasions (the  23 
following week).   24 
  25 
After the initial tests, you will participate in a 12 week training programme.  26 
Strength training of the quadriceps (thigh) muscle group will take place on a leg  27 
extension device, 3 times per week for 12 weeks.  Each training session will  28 
consist of 1 "warm-up" set of 10 repetitions at 75 % of the training load, and 4  29 
sets of 10 repetitions at 100 % of the training load. Rest periods of 1 minute will  30 
separate sets. The training load is defined as that load which can be used with  31 
successful completion of 10 repetitions and no more (10-RM load) - estimated at  32 
70 % 1-RM. Your 1-RM will be re-assessed weekly, and the training load adjusted  33 
as necessary to maintain a constant training stimulus. All training sessions will be  34   109 
conducted  in  the  university  and/or  hospital  laboratories,  and  all  will  be  1 
supervised.  2 
  3 
After the 12-week training programme, you will be required to repeat all initial  4 
assessments (including the muscle biopsy).  5 
  6 
During the initial and final assessments we would like to take a small amount of  7 
blood  from  a  vein  in  your  forearm  to  assess  blood  levels  of  ACE  and  which  8 
genetic  variant  of  this  enzyme  and  the  p21  protein  you  have.  Your  genetic  9 
material will not be used for any other purpose than that specified here.  10 
  11 
What  are  the  side  effects  of  taking  part?  A small scar at the muscle biopsy  12 
sample site is not uncommon; this typically resolves over a period of months. The  13 
blood sample may also cause some bruising and subsequent soreness over the  14 
site of puncture and, rarely, a small wound that takes a few days to heal.  15 
  16 
What are the possible disadvantages and risks of taking part? There are no  17 
serious risks of having a muscle sample taken from your thigh by means of a fine  18 
needle. There is a small risk of inducing local pain, bruising, bleeding or infection.  19 
A small diameter biopsy needle and the use of local anaesthesia will minimize  20 
these risks.  21 
  22 
Exercise has a negligible risk in healthy adults, although maximal exercise has a  23 
small  risk  of  inducing  myocardial  ischaemia  ("heart  attack").  The  primary  24 
symptom of myocardial ischaemia is chest pain on exertion. If you experience  25 
any unusual sensations in your chest during the experiment, you should cease  26 
exercising immediately.  27 
  28 
What are the possible benefits of taking part? We hope that you will find out  29 
more about how your body responds to strength training. This information may  30 
help us better understand the mechanisms by which muscle adapts to strength  31 
training.  32 
  33 
What if something goes wrong? If you are harmed by taking part in this research  34 
project,  there are no  compensation arrangements.  If  you  are  harmed due to  35   110 
someone's negligence, then you may have grounds for a legal action but you may  1 
have to pay for it. The principal investigators, although not medically qualified  2 
are fully trained in Advanced Life Support. In the event of an untoward incident,  3 
the  principal  investigator(s)  will  provide  basic  life  support  including  chest  4 
compressions  and  ventilation,  and  will  apply  an  advisory  defibrillator  (if  5 
necessary) until emergency medical staff are on hand. The taking of the biopsies  6 
will be carried out my experienced medically qualified investigators.  7 
  8 
Will my taking part in this study be kept confidential? All information which is  9 
collected  about  you  during  the  course  of  the  research  will  be  kept  strictly  10 
confidential.  11 
  12 
What  will  happen  to  the  results  of  the  research  study?  Results  will  be  13 
published in a peer-reviewed scientific journal once the study is completed. You  14 
will  automatically  be  sent  a  copy  of  the  full  publication.  You  will  not  be  15 
identified in any publication.  16 
  17 
  18 
  19 
  20 
  21 
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  1 
Table 5: Schedule of visits and proposed tests.  2 
  3 
Visit  Test  Duration (hrs) 
1  Physical characteristics, questionnaires, muscle 
biopsy and familiarisation of strength test 
2 
2  Strength test  1 
3  Strength test  1 
  12  week  strength  training  programme  (3  x 
week) 
18-20 
4  Muscle biopsy  0.5 
5  Strength test  1 
6  Strength test  1 
  4 
If you wish to find out more about this investigation, you can contact:  5 
  6 
Dr Yannis Pitsiladis  7 
Lecturer, Institute of Biomedical and Life Sciences  8 
West Medical Building  9 
University of Glasgow  10 
Glasgow, G12 8QQ   11 
Phone: 0141 330 3858  12 
Fax: 0141 330 6542  13 
e-mail: Y.Pitsiladis@bio.gla.ac.uk  14 
  15 
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CONSENT FORM 
 
Consent Form 
 
I   ...........................................................  
 
give my consent to the research procedures which are outlined above, 
the aim, procedures and possible consequences  of which have been 
outlined to me 
 
 
Signature  ……………………………………… 
 
Date    ……………………………………… 
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